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ABSTRACT
Tamoxifen resistance is the biggest problem in endocrine treatment against
hormone receptor positive breast cancer patients. HER2 is a membrane receptor
tyrosine kinase that is known to correlate with poor disease outcome and
unresponsiveness to endocrine treatment. Although much work has been done
over the past decades to elucidate pathways involved in HER2 receptor signaling,
the map of network-wide signaling events that contributes to the resistance to
Tamoxifen treatment has not been characterized, making it difficult to pin-point the
downstream drug target to revert the Tamoxifen resistance. To gain a molecular
understanding of the mechanisms by which cells gain drug resistance, we have
employed a proteomic analysis by mass spectrometry to quantitatively analyze
cellular tyrosine phosphorylation signaling events in breast cancer model systems
and human tumor samples.
As a result of research, we have identified the major differences in
downstream signaling pathways between Tamoxifen sensitive and Tamoxifen
resistant breast cancer cell line models. These findings were further analyzed in
Tamoxifen sensitive, and Tamoxifen treated/recurred patient samples to study
clinical relevance. Specifically, we determined that P13K/Akt, MEK/ERK, and
Src/FAK/Abl pathways are major components of the Tamoxifen resistance. We
further showed that they signaling components are possible drug targets to revert
Tamoxifen resistance. This study revealed cell-context specific network-wide
changes in signaling events in response to use of therapeutic drugs. This is, to our
first knowledge, the first phosphoproteomic analysis of the signaling network in
breast cancer to address Tamoxifen resistance. We believe that same approach is
applicable to other drug resistance problems in various disease settings.
Thesis Supervisor: Forest M. White
Title: Associate Professor of Biological Engineering
I. INTRODUCTION
The current state of breast cancer treatment,
Phosphoproteomic technologies, and
Phosphorylation signaling networks.
The current state of breast cancer treatment
1.1.1 Breast cancer and endocrine therapy
Breast cancer accounts for approximately 30% of all new cancer cases
each year in developed countries, with an annual incidence of over 200,000 in the
United States alone (Jemal et al., 2006). Approximately 70% of breast cancer
patients are candidates for endocrine therapy because of their hormone receptor
positive cancers (Anderson et al., 2002). These patients express estrogen
receptor (ER), a member of nuclear hormone receptor family. Estrogen signals
through ER to stimulate growth of hormone receptor breast cancers. Endocrine
therapy targeting estrogen receptor biology plays a role in disease management
and significantly improves the clinical outcomes of patients with ER positive breast
cancers.
Today, two classes of anti-estrogen agents are considered the standards of
care for primary treatment of early- or advanced-stage ER' breast cancers.
Tamoxifen, a selective estrogen receptor modulator (SERM) which blocks ER
1. 1
activity within breast tumor cells, has been used for over 30 years and has been the
standard choice. Newer generation endocrine therapeutic agents, anastrozole,
letrozole, or exemestane, known collectively as the Aromatase inhibitors (Als),
inhibit the production of estrogen through inhibition of the aromatase enzyme
pathway in multiple organs including ovaries. Tamoxifen has advantage over Als
in its efficacy in both premenopausal and postmenopausal women, whereas Als are
approved for its use only in postmenopausal women. Since its FDA approval in
1986, Tamoxifen has been tested over decades of clinical studies while Als have
been in clinical use since 1995 when Anastrozole became the first approved Al for
breast cancers with disease progression following Tamoxifen therapy. Tamoxifen
extends the disease-free survival period of breast cancer patients by approximately
2 years relative to placebo in the adjuvant treatment after surgical removal of breast
cancers (Fisher et al., 1996). In addition to the adjuvant treatment, Tamoxifen is
approved for the prevention of breast cancer in women who have a high risk of
developing breast cancers based on their family history (Fisher et al., 1998). In the
adjuvant treatment, several studies have demonstrated that Als are better tolerated
at higher dose and offer improved disease-free survival compared to Tamoxifen
(Coates et al., 2007; Coombes et al., 2007; Forbes et al., 2008).
Als have also been demonstrated in the late stage metastatic tumors (Bonneterre et
al., 2000; Mouridsen et al., 2003; Nabholtz et al., 2000; Paridaens et al., 2003) and
neoadjuvant settings (Eiermann et al., 2001; Ellis and Ma, 2007; Smith and Dowsett,
2003). Although Tamoxifen remains the most popular choice amongst patients, I
predict that the aromatase inhibitor treatment will become more common once a
long-term safety profile is established and the cost of treatment becomes
comparable to Tamoxifen treatment, making Als widely available around the world.
Despite an initial response to hormone therapy in all treatment settings
(primary, adjuvant, or neoadjuvant), breast cancers in many patients progress
during therapy. Although it is standard practice in recurrent or resistant ER' breast
cancer to switch to a different endocrine agent, many questions remain unanswered
regarding the appropriate choice of subsequent agents to combat the resistant
tumors. In any event, the goals of treatment for patients with metastatic breast
cancer are to provide clinical benefits - namely stabilizing the disease state with the
aim of prolonging life and delaying disease progression, maintaining quality of life
(QOL), and postponing the use of cytotoxic chemotherapy that further impairs QOL.
The benefits of
1.1.2 Mechanisms of estrogen receptor functions
The classic mechanism of estrogen receptor function involves the estrogen
binding to ER in the nucleus, thereby promoting association with specific
estrogen-responsive elements (EREs) in the promoter region of controlled genes
(Jensen et al., 1982). The binding of estrogen to the nuclear ER induces a series
of actions leading to activation of the ER. Prior to activation, the ER is stably
associated with heat shock proteins in an inactive state. Upon estrogen binding,
ER dissociates from the heat shock proteins, undergoes conformational changes,
homodimerizes, and undergoes phosphorylation at multiple key serine residues
(Osborne and Schiff, 2005). Fully activated ER homodimers binds to EREs,
resulting in recruitment of RNA polymerase to initiate gene expression. In addition
to classical modes of ER function through EREs, ER can regulate gene expressions
of genes without EREs via interaction with other transcription factors. The ER can
interact with transcription factors such as the Fos-Jun complex to regulate gene
regulatory DNA sequences other than classic EREexpression at alternative
containing genes (Kushner et al., 2000).
In addition to its roles in nucleus, ER is present outside of nucleus and can
regulate the activity of membrane bound receptor tyrosine kinases and cytosolic
kinases such as EGFR, HER2, IGF1-R, P13K, and MAPK (Bjornstrom and Sjoberg,
2005; Chung et al., 2002; Kahlert et al., 2000; Levin, 2003; Migliaccio et al., 1996;
Schiff et al., 2004; Sun et al., 2001). Besides kinases, ER binds to specific G
proteins and activates Src which results in matrix metalloproteinases that cleave
transmembrane precursors of heparin binding-EGF (Levin, 2003; Razandi et al.,
2003). In additions to the modulations of kinase activities by ER, ER can be
activated in the absence of estrogen via phosphorylation by different intracellular
kinases. This mode of ER activation is called the ligand-independent activation
(Johnston, 2005). The ER is phosphorylated at Serine 118, Serine 167, and
Threonine 311, and these phosphorylation events may be due to activation of
MAPK, P13K/Akt, p90RSK pathways and the phosphorylation could occur in
response to various cytokines and growth factor stimulation in the absence of
estrogen (Campbell et al., 2001; Joel et al., 1998; Kato et al., 1995). The ER
phosphorylated in a ligand-independent manner can also translocate to nucleus,
and activate transcription at genes with the EREs.
L 1.3 Current understanding of endocrine resistance mechanisms
With increased understanding of the complex, interconnecting estrogen-ER
signaling pathways that regulate cellular responses, it has become clear that tumor
cells take different approaches to become resistant to the anti-estrogen therapy.
Unraveling the complexity is essential for making the best decisions regarding
treatment options, sequencing of currently available therapeutics, and developing
future therapeutic compounds. The resistance to therapy is described either as
initial (a tumor does not respond to a drug from the onset of therapy, which also
often called intrinsic or de novo) or acquired (a tumor that initially responded to
therapy resumes growth) (Johnston, 1997; Normanno et al., 2005). Approximately
70% of early stage and 50% of advanced stage ER' breast cancer patients benefit
from Tamoxifen treatment, whereas the remaining patients suffer from initial
resistance. In addition, up to 40% of the Tamoxifen responsive breast cancer
patients suffer from recurrence due to acquired resistance. Interestingly, the
majority of these patients remain ER*, indicating that the therapeutic target remains
present in the tumor cells. Acquired resistance is currently thought to be a
progressive, step-wise phenomenon. The acquired resistance is induced by the
selective pressures from the hormonal agents, which drive breast cancer cells from
the estrogen-dependent to the endocrine non-responsive phonotype. The finding
that ER expression is maintained in the majority of Tamoxifen resistant tumors
suggests that the acquired resistance phenotype is caused by complex,
multifactorial changes in the ER signaling network rather than a simple, single-gene
effect. This also may explain why approximately two thirds of breast cancer
patients who developed acquired Tamoxifen resistance and recurrent disease
remain responsive to Als (Lewis and Jordan, 2005), suggesting that the acquired
resistance tumor cells remain the estrogen dependent for growth.
1. 1.4 Altered growth factor receptor signaling in endocrine resistance.
Altered activities of growth factor receptors resulting in deregulated
signaling networks are common to therapeutic resistance in many forms of cancer,
and may contribute to the anti-estrogen resistance in the ER* breast tumors.
Almost 30% of breast cancers are noted to overexpress the human epidermal
growth factor receptor 2 (HER2, also termed ErbB2, neu), a member of the
epidermal growth factor receptor (EGFR) tyrosine kinase family. Data from
preclinical studies and from the retrospective analyses of clinical trials suggest that
HER2 is a negative predictor of the response to Tamoxifen treatment (Benz et al.,
1992; Dowsett et al., 2008). HER2 and ER cross-talk to stimulate their activities in
a cellular model of Tamoxifen resistance (Shou et al., 2004). Our understanding of
the mechanisms and outcomes of cross-talk between the ER and HER2 signaling
networks remains incomplete. Although the ligand-independent activation of ER
has shown to play an important role in ER phosphorylation and activation, how ER
communicates back to the HER2 signaling pathway remains unclear.
.1.5 Effects of the long-term estrogen deprivation by endocrine therapy
Human breast cancer cells that are deprived of estrogen can adapt by
developing estrogen hypersensitivity (Masamura et al., 1995; Santen et al., 2005).
Development of estrogen hypersensitivity may explain the clinical observation that
estrogen-dependent breast cancer that initially regressed after ovaryectomy-
induced estrogen deprivation in premenopausal women re-grew in response to
low-dose estrogen replacement therapy and subsequently regressed further after
exposure to Als. Additional data suggest that breast cancer cell lines subjected to
long-term estrogen-deprivation demonstrate step-wise progression whereby they
first become hypersensitive to low-dose estrogen and eventually become estrogen
independent (Chan et al., 2002). One possible mechanism to explain such
acquired hypersensitivity and resulting estrogen-independent ER activity is
increased ligand-independent ER phosphorylation.
L.1.6 Sequential endocrine therapy to treat resistance
When initial or acquired resistance to the endocrine therapy occurs, no
effective treatment guidelines exist regarding subsequent hormone treatments for
patients with recurrent or systemic diseases. Although the National
Comprehensive Cancer Network recommends a second-line hormone therapy such
as nonsteroidal or steroidal Als; fulvestrant or other SERMs, the guideline does not
recommend a preferred treatment or the appropriate sequencing of agents for
recurrent breast cancer after endocrine treatment (Cancer guideline, Accessed
March 1st 2009). Forty to fifty percent of patients with breast cancer who have a
response to the initial hormone therapy will respond to subsequent treatments with
agents with a different mechanisms of action from the initial therapy (Buchholz et al.,
1999). Although sequential endocrine therapy is beneficial for postponing
aggressive chemotherapy, the eventual development of resistance to sequential
second-line endocrine therapy seems unavoidable.
I. 1.7 Hormonal treatments in ER*/HER breast cancer patients
HER2 overexpression in breast cancers strongly correlates with poor
disease outcomes (Slamon et al., 1987). From this aspect, it is not surprising that
ER*/HER2* patients do not respond particularly well to endocrine therapies
compared to ER*/HER2~ patients. The first evidence of a potential negative
correlation between the expression of HER2 and the response to Tamoxifen
from the Gruppo Universitario Napoletano (GUN)-1 study which
evaluated the HER2 expression levels in 145 out of 309 lymph-node negative
breast cancer patients. The adjuvant Tamoxifen treatments were associated with
the improved disease-free survival (DFS) and the overall survival (OS) in the HER2~
patients but the treatments were associated with worse DFS and OS in the HER2*
patients (Carlomagno et al., 1996; De Placido et al., 2003). In agreement with this
finding, studies conducted in Sweden found that the HER2*patients did not further
benefit from five years of Tamoxifen treatment compared to the placebo, whereas
HER2~ patients significantly benefited from such treatment. Several retrospective
analyses of studies with Tamoxifen treatments in advanced breast cancers showed
worse outcomes for the patients expressing high levels of HER2 than the HER2-
patients (Elledge et al., 1998; Wright et al., 1992). These results show that
Tamoxifen is not the optimal treatment option for all ER* patients and that other
disease markers, such as HER2, should be taken into account before the start of
endocrine treatments, including but not limited to Tamoxifen treatments.
The availability of novel anti-estrogenic therapeutics such as the Als has
instigated investigations into the efficacy of these therapeutic compounds compared
originated
to Tamoxifen in breast cancer patients with HER2 overexpression.
showed that the non-steroidal aromatase inhibitor Letrozole is superior to
Tamoxifen as a first-line therapy independent of serum HER2 levels (Lipton et al.,
2003). Furthermore, the retrospective analyses of data collected in the trials of
neoadjuvant endocrine therapies comparing Letrozole treatments versus Tamoxifen
treatments found that the response rate is significantly higher for Letrozole
compared with Tamoxifen in the subgroup of patients with EGFR or HER2
expression (Ellis et al., 2001). Unfortunately, the relatively small sample numbers
from these two studies makes it challenging to generalize that Als are superior to
Tamoxifen for ER' patients regardless of HER2 status. However, these studies
that the ER functions are affected by the binding of estrogen
anti-estrogen in cell specific manners and the results may significantly influence the
clinical guideline.
L.1.8 The current status of the integration of endocrine therapies and kinase
inhibitors
suggest
Lipton et al
Since perturbed growth factor signaling events may play significant roles in
the both initial and acquired Tamoxifen resistance in breast cancer cells, the use of
combinatorial treatments to inhibit both ER and the signal transduction mediated by
kinases represents one of the most promising therapeutic approaches. In this
respect, therapeutic compounds inhibiting signaling molecules such as HER2,
EGFR, IGF1-R, Ras/Raf/MEK/MAPK, P13K/Akt, and c-Met are currently in clinical
developments. The results from the cell line studies indicated that combinatorial
treatment might be effective in both hormone-sensitive and hormone-resistant
breast cancer patients. In many cases, the combinatorial treatments are reported
to be additive or synergistic in killing the Tamoxifen resistant model cell lines. For
example, farnesyl transferase inhibitors that target Ras activity were synergistic with
Tamoxifen or aromatase inhibitor treatments against multiple breast cancer cell
lines (Ellis et al., 2003; Liu et al., 2007). Similar results were obtained with the
combination of mammalian target of rapamycin (mTOR) inhibitors with Letrozole in
multiple breast cancer cell line models (Boulay et al., 2005). A synergistic
anti-tumor effect has been reported for the anti-HER2 humanized monoclonal
antibody Herceptin in combination with Tamoxifen against ER*/HER2+ cell line
models (Argiris et al., 2004; Ropero et al., 2004). Finally, the combined treatments
of the EGFR inhibitor Iressa and Tamoxifen were effective against the breast cancer
cell line models with acquired Tamoxifen resistance (Gee et al., 2003). These cell
line studies show that the combinations of signal transduction inhibitors with
endocrine therapy may be more effective in the first line treatment of ER' breast
cancer patients than endocrine therapy alone. In addition, such combinations of
treatments have the potential to prevent the development of acquired resistance as
the signaling molecules proposed to facilitate acquired resistance are inhibited
along with ER. However, as discussed in the clinical trials of the combinatorial
therapy in the following section, the combinatory treatments still have room for
improvements. One of the main reasons for the lack of desired efficacy is that
many breast tumors are heterogeneous populations. The combinatorial
treatments described above are mostly conducted in a single model cell line system
(for example, the overexpression of HER2 in a MCF7 cell line). This limits the
identification of better therapeutic approaches that are effective against
heterogeneous tumor populations. Therefore, the successful identification of a
therapeutic approach to endocrine resistance requires evaluation of perturbed
signal transductions that are common to multiple endocrine resistant cell line
models.
1.1.9 Clinical trials of combinatory treatments against ER breast cancer
patients
There are a few published reports on the clinical trials for the combination of
endocrine therapy and kinase inhibitors in the breast cancer patients.
Encouraging preliminary results have been disclosed from the trial testing a
combinatorial treatment of Herceptin and Letrozole in ER*/HER2* advanced breast
cancer patients (Marcom et al., 2007). Combined Herceptin and Letrozole
treatments produced durable responses for a half of the patients, whereas the
combination was ineffective in the other half. The finding suggests that
ER*/HER2* advanced breast cancers are heterogeneous and could be divided
further into subgroups. The finding also suggests that additional therapeutic
agents are required in order to manage ER*/HER2* advanced breast cancers. In
the case of neoadjuvant combination treatment of ER*/EGFR* patients with Iressa
and the non-steroidal aromatase inhibitor Anastrazole, the combinatorial treatment
was effective in reducing the pretreatment values in proliferation-related Ki67
labelling index than Iressa alone (Polychronis et al., 2005). The size of breast
tumors was reduced by 30-99% in 14/28 patients in the combinatorial treatment
group, while administrations of Iressa alone reduced the size of breast tumor in
12/22 cases, and both the combinatorial treatment and Iressa treatment reduced
phosphorylation of ER at Ser 118 at a similar extent. These results indicates that
combinatorial treatments of endocrine therapy and kinase inhibitors are tolerated
and may be effective in subgroups of ER*/EGFR* breast cancer patients.
The following two sections in the chapter 1 are from the published
review titled "Quantitative phosphoproteomics by mass spectrometry:
Past, Present, and Future" in the Proteomics volume 8, Issue 21, Page
4433-4443.
I. 2 Phosphoproteomic technologies
I. 3 Phosphorylation signaling networks
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REVIEW
Quantitative phosphoproteomics by mass spectrometry:
Past, present, and future
Aleksandra Nita-Lazar' *, Hideshiro Saito-Benz' * and Forest M. White1,2
1 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
2 Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
Protein phosphorylation-mediated signaling networks regulate much of the cellular response to
external stimuli, and dysregulation in these networks has been linked to multiple disease states.
Significant advancements have been made over the past decade to enable the analysis and
quantification of cellular protein phosphorylation events, but comprehensive analysis of the
phosphoproteome is still lacking, as is the ability to monitor signaling at the network level while
comprehending the biological implications of each phosphorylation site. In this review we
highlight many of the technological advances over the past decade and describe some ofthe latest
applications of these tools to uncover signaling networks in a variety of biological settings. We
finish with a concise discussion of the future of the field, including additional advances that are
required to link protein phosphorylation analysis with biological insight.
Keywords:
Electrospray ionization-tandem mass spectrometry / Protein phosphorylation / Signal
transduction profiling / Spectrometry
1 Introduction
In the postgenomic era rapid advancement in the character-
ization of new genes and their protein products has driven
an increased demand to functionally classify these proteins.
Classical genetic, biochemical, and protein chemical
approaches have been historically used to tackle this chal-
lerige for selected biomolecules, but these methods tend to
be time-consuming, laborious, and usually require large
amounts of material. Application of these approaches to
Correspondence: Dr. Forest M. White, Department of Biological
Engineering, Massachusetts Institute of Technology, Cambridge,
MA 02139, USA
E-mail: fwhite@mit.edu
Fax: + 1-617-258-0225
Abbreviations: EGFR, epidermal growth factor receptor; HMEC,
human mammary epithelial cells; IMAC, immobilized metal affin-
ity chromatography; IP, immunoprecipitation; NSCLC, nonsmall
cell lung cancer; PLSR, partial least squares regressions; SCX,
strong cation exchange; SILAC, stable-isotope labeling of amino
acids in cell culture
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characterize thousands of proteins is therefore unrealistic.
However, recently developed proteomic methods, quickly
improving with technical advancements in equipment, per-
mit large-scale protein analysis while maintaining molecular
resolution. While these large-scale methods do not directly
provide functional characterization, they can be used to gen-
erate hypotheses regarding the function of selected proteins.
Follow-on biochemical studies can then be performed on
these proteins to validate hypotheses.
Functional classification is further complicated by pro-
tein PTMs, which can modify enzymatic activity, binding
affinities, and protein conformation. Among PTMs, phos-
phorylation is perhaps the best studied due to the association
between dysregulated phosphorylation and human patholo-
gies [1]. Protein phosphorylation on Ser (-90%), Thr
(-10%), and Tyr (-<0.05% of protein phosphorylation)
residues is reversible and its dynamic addition can produce
fast and precise changes in protein properties, which in turn
affect many critical processes, such as protein-protein inter-
actions, cell signaling, cytoskeleton remodeling, cell cycle
* Both these authors contributed equally.
www.proteomics-journal.com
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events, and cell-cell interactions [2]. Protein phosphorylation
analysis is still very challenging, although breakthrough
developments over the past decade have now enabled the
identification and quantification of thousands of sites from
given biological samples. To put these advancements in the
field of phosphoproteomics into perspective, Fig. 1 high-
lights several of the most significant publications over the
past 7 years.
Our focus in this review is on quantitative phosphopro-
teomics by MS. Here we discuss the latest developments in
the field, including instrumentation, reagents, and enrich-
ment techniques. Selected applications are highlighted to
demonstrate the capabilities of these methods, with an eye
toward quantification of signaling networks and use of this
information for drug target discovery (for recent reviews, see
ref. [3, 4]).
2 Challenges of phosphoproteomics
Phosphoproteomic analysis is plagued by the same chal-
lenges facing all proteomic experiments: complexity, dy-
namic range, and temporal dynamics. The true complexity of
the phosphoproteome has yet to be determined, but the
Phosphosite database (http://www.phosphosite.org) now
lists >30 000 phosphorylation sites on >17 000 proteins, and
this number is steadily increasing as each large-scale phos-
phorylation analysis continues to identify a large number of
novel sites. With so many of the proteins in the cell being
2004:Use of anti-
phosphotyrosine antibodies
for phosphopeptide
immunoprecipitation;
Rush eta.
2001: -elimination to
probe yeast
phosphorylation;
Oda et a,
2001: Phosphoramidate
chemistry for enrichment
of yeast phoshopeptides;
Zhou et at
2002: IMAC of methyl-
ester modified peptides
applied to yeast
phosphoproteome;
Ficarro et al.
2004:Use of SCX as an
enrichment method for
phosphoproteomics;
Beausoleil et a.
2004: Development of
ETD; Syka et aL
2004: Temporal analysis
of EGFR signaling by
SILAC; Blagoev et al.
phosphorylated, the dynamic range of the phosphoproteome
is similar to that of the proteome (i.e., -109), but is further
increased by substoichiometric modification. In addition, the
temporal dynamics of protein phosphorylation regulate the
rapid activation and deactivation of cellular signaling net-
works, further complicating analysis of the phosphopro-
teome. So the challenge is not simply to identify and catalog
all of the phosphorylation sites, but rather to identify the site,
quantify the stoichiometry, and monitor the temporal change
in phosphorylation in response to a variety of cellular per-
turbations. Performing this task on a large number of phos-
phorylation sites across a broad swath of the signaling net-
work is especially challenging, but is required to understand
the mechanisms by which protein phosphorylation controls
cell biology.
3 Enrichment methods
Phosphorylated proteins span the gamut of protein expres-
sion level, from hundreds of millions to a few copies per cell.
However, many of the phosphorylation events associated
with canonical cellular signaling pathways occur on proteins
expressed at relatively low levels. Since phosphorylation of
these proteins is often substoichiometric and transient,
phosphopeptides obtained from these proteins after proteo-
lytic digest are nearly impossible to detect in the whole cell
lysate or tissue sample, which can generate potentially mil-
lions of peptides. Selective enrichment of phosphorylated
2007:Use of MRM for
phosphoproteomic
analysis of cell signaling;
Wolf-Yadlin et al
2007:Use of ETD for
global phosphorylation
analysis; Chi et aL.
2007: Large-scale analysis
of lung cancer samples by
phosphotyrosine peptide
IP: Rikov et al.
2006: SCX-TiO2 double
enrichment of SILAC
labeled peptides for EGFR
signaling analysis; Olsen et
a.
Figure 1. Timeline of selected milestones in quantitative phosphoproteomics during the last decade. Each publication has been selected
based on implementation of a new method or application of recently developed methodology to uncover novel aspects of signaling net-
works.
@ 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
2005: Site-specific
quantification of EGFR
signaling by
phosphotyrosine peptide IP
and ITRAQ; Zhan et a.
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peptides and proteins is required and has been accomplished
in a number of ways, including antiphosphotyrosine anti-
bodies [5], immobilized metal affinity chromatography
(IMAC) [6], chemical modification, and strong cation
exchange chromatography (SCX) [7].
Immunoprecipitation (IP) of tyrosine phosphorylated
proteins and peptides with high affinity antiphosphotyrosine
antibodies [8] provides good yield and specificity and has
been demonstrated on a broad variety of applications [9-12].
Several reliable antiphosphotyrosine antibodies are sold
commercially. These antibodies primarily recognize phos-
photyrosine, but each has some bias toward the surrounding
amino acids, and therefore performing the IP with multiple
antibodies may increase coverage of the tyrosine phospho-
proteome. Since the fraction of tyrosine phosphorylated pro-
tein to total protein may vary significantly from sample to
sample, experimental optimization of conditions, including
relative amount of antibody to total sample protein, is often
necessary to reduce nonspecific binding while maximizing
yield for the particular sample. It is worth noting that while
IP has been succesfully implemented for tyrosine phospho-
rylation, anecdotal evidence indicates that the analogous
pan-specific antibodies against phosphoserine and phospho-
threonine tend to be of lower affinity, and therefore yield
unsatisfactory enrichment for these subsets of phosphoryl-
ated peptides. However, recent work by Matsuoka et al. [13]
has demonstrated the potential of using multiple phospho-
specific antibodies recognizing ATM/ATR substrate phos-
phorylation sites to identify and quantify hundreds of serine
and threonine phosphorylation sites matching the ATM/
ATR kinase motif. Since many phospho-specific antibodies
have off-target affinity, it may be that this strategy could be
applied to a variety of serine/threonine kinases, effectively
supplementing the need for high affinity pan-specific phos-
pho-serine/threonine antibodies, and enabling network
analysis of serine/threonine phosphorylation, one motif at a
time.
For many applications, the goal is to generate a global
view of serine, threonine, and tyrosine phosphorylation
within the sample rather than focusing specifically on a
selected subset of phosphorylated peptides. Perhaps the
most common technique to enrich for global phosphoryla-
tion is IMAC, which is based on the high affinity of phos-
phate groups for metal ions such as Fe", Zn2 +, and Ga".
One of the main limitations associated with IMAC-based
phosphopeptide enrichment has been the nonspecific reten-
tion of nonphosphorylated acidic peptides, due to the weak
affinity between negatively charged carboxylates and posi-
tively charged metal ions. However, conversion of carboxylate
groups to esters effectively eliminates nonspecific retention
of nonphosphorylated peptides on the IMAC column [14].
This method has also been used in an automated platform
involving online IMAC, nano-LC, and ESI-MS, enabling re-
producible detection and identification of phosphopeptides
in a low-femtomole range [15], and may be coupled with a
stable-isotope labeling step for relative quantification [14].
@ 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Since different metal ions appear to enrich for slightly dif-
ferent subsets of phosphorylated peptides, maximal coverage
of the phosphoproteome may be obtained by multiple analy-
ses with different metals, or by mixing multiple metal ions in
a single IMAC enrichment step.
Within the past couple of years, titanium dioxide (TiO2)
has emerged as the most common of the metal oxide affinity
chromatography (MOAC)-based phosphopeptide enrich-
ment methods. This technique requires significantly shorter
preparation time and offers increased capacity relative to
IMAC resins with the same bed volume. Since this method
exploits the same principle as IMAC, it is similarly prone to
nonspecific retention of acidic nonphosphorylated peptides.
However, loading peptides in 2,5-dihydroxybenzoic acid has
been shown to reduce nonspecific binding to TiO 2, thereby
improving phosphopeptide enrichment without chemical
modification of the sample [16]. Overall, TiO 2 is often con-
sidered to be interchangeable with IMAC, in that similar
sample levels (e.g., micrograms of protein) can be analyzed
and hundreds of sites per sample can be identified when
either technique is used as the sole enrichment method, al-
though each method has demonstrated differential bias and
selectivity.
As an alternative to metal-ion-based enrichment strate-
gies, SCX has been successfully used to separate phospho-
rylated peptides from peptide mixtures for subsequent MS
analysis [7, 16, 17]. In this technique, binding to the SCX
column is dependent on columbic interaction between
negatively charged resin and positively charged peptides. If
sample loading is performed under strong acidic conditions
(pH -2.7), carboxylates are rendered neutral, while the
phosphate group retains a negative charge. As a result, the
total charge of phosphorylated tryptic peptides is reduced
from + 2 to + 1, and the interaction strength with the SCX
resin is correspondingly reduced. Elution with a gradient of
increasing salt concentration thus allows phosphopeptides to
elute earlier relative to nonphosphorylated peptides, provid-
ing semiselective enrichment [7]. To reduce the nonphos-
phopeptide background, a second, IMAC-based enrichment
step has been performed on SCX fractions, enabling the
identification of thousands of phosphorylated peptides from
given samples [7, 17, 181. As another variation and improve-
ment of the SCX method, a mixed-bed resin comprised of a
blend of anion and cation exchangers (ACE) has been
recently proposed for phosphopeptide enrichment, increas-
ing retention of acidic peptides, and reducing retention of
basic and neutral peptides by the added anion-exchange
resin, which in turn improved the identifications of phos-
phopeptides by 94% over SCX [19].
Phosphorylation enrichment by SCX-based fractiona-
tion, either solely or coupled with other enrichment steps,
has successfully been applied to identify large numbers of
phosphorylation sites (in the order of thousands). However,
it is worth noting that the technique, as implemented to date,
requires a large amount of starting material (tens of milli-
grams of protein) which makes it inapplicable to samples
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that are available in small or limited quantity. In addition,
SCX fractionation decreases the complexity of the starting
samples by dividing it into many fractions, each of which
requires a separate MS analysis, leading to the possibility of
up to 100 MS analyses for each biological replicate. The
sample requirements, analysis time, and labor associated
with each biological sample has unfortunately limited the
application of this technique such that few studies have
incorporated biological replicates.
Several laboratories have taken the approach of chemi-
cally modifying the phosphate to provide an affinity enrich-
ment tag. For instance, the phosphate groups on serine and
threonine can be removed by -elimination and replaced by
ethanedithiol coupled to a biotin tag, making it possible to
purify modified peptides using an avidin affinity column
[20]. The primary disadvantage of this approach is that tyro-
sine phosphorylation does not undergo p-elimination, and
therefore these peptides are not enriched by this method. It
is also possible to directly attach an affinity tag to the phos-
phate through phosphoramidate chemistry (PAC). Recent
improvements in this approach have improved the yield by
reducing the number of steps, making the approach much
more user-friendly [21].
Different enrichment methods may yield different pools
of phosphopeptides from the same peptide mixture, as
recently shown in a comparative study conducted by the
Aebersold group, where PAC, IMAC, and two types of TiO2
methods were employed to isolate phosphopeptides from a
tryptic digest of Drosophila melanogaster Kc167 cells [22]. Per-
forming multiple analyses with several complementary
phosphopeptide enrichment methods may be the best way to
maximize depth of coverage, albeit at the cost of increased
sample consumption and reduced throughput.
It is often the case that any single enrichment step does
not provide sufficient specificity when dealing with complex
biological samples. Therefore, double enrichment, as in the
above scenario with IMAC and SCX, is often required to
improve phosphopeptide analysis. In another example, our
laboratory has combined antiphosphotyrosine peptide IP
with IMAC to analyze tyrosine phosphorylation in murine
adipocytes [23], human Jurkat cells [24], and in the epidermal
growth factor receptor (EGFR) signaling network in human
mammary epithelial cells (H MECs) [25, 26].
4 Quantification approaches
To date much of the work in phosphoproteomics has focused
on developing novel methods for the enrichment of phos-
phorylated peptides/proteins and subsequent application of
these methods to identify large numbers of phosphorylation
sites from given biological samples. Data generated in these
"cataloging" studies may be informative for laboratories
studying selected proteins whose phosphorylation sites
appear in the catalog, but it is often difficult to link the
information in these large-scale datasets to cellular signaling
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networks. In order to identify phosphorylation events that
may be regulating biological response to cellular perturba-
tion, quantification of phosphorylation pre- and post-cell
stimulation is necessary. Several MS-based quantification
methods have been implemented for phosphoproteomics,
including stable-isotope labeling through chemical mod-
ification of peptides, stable-isotope labeling of amino acids in
cell culture (SILAC), and label-free methods.
Multiple chemical modification protocols have been uti-
lized to incorporate stable isotopes; among these methods,
iTRAQ has become the most commonly used option due to
its multiplex capability. The iTRAQ reagent consists of four
isobaric isoforms which react with primary amines, thereby
enabling quantitative comparison of four protein samples in
parallel. Since the labels are isobaric, quantification is per-
formed in MS/MS mode by comparing peak areas of the
marker ions resulting from fragmentation of the iTRAQ
label, so the same spectrum is used for quantification and
sequence identification of the phosphopeptide. As demon-
strated in Fig. 2, when coupled to phosphotyrosine peptide
IP and IMAC, iTRAQ has been successfully applied for the
quantification of phosphorylation states of differentially
stimulated Jurkat cells [24], adipocytes [23], and for analysis
of the temporal dynamics of the ErbB signaling network [25,
26]. Recently, the eight-plex version of iTRAQ has been
developed and applied to proteome analysis [27], demon-
strating the potential to further increase throughput in
quantitative proteomic analysis, but this reagent has yet to be
used for the quantification of protein phosphophorylation.
For metabolic isotope labeling, cells are cultured in a
medium where the natural form of an amino acid (typically
arginine or lysine) is replaced with a stable isotope form,
such that proteins expressed by the cell incorporate the hea-
vier version of this amino acid and therefore alter their mo-
lecular mass (see ref. [28] for the detailed, updated review of
the method). This technique is generally referred to as
SILAC, and enables comparison of up to three samples in a
single analysis. Initially, SILAC was developed for mamma-
lian cells [29], but its use has been broadened to bacteria [30]
and yeast [17]. There have also been reports of in vivo meta-
bolic labeling in whole organisms (Plasmodium falciparum
[31], plants [32], D. melanogaster, Caenorhabditis elegans [33],
and rats [34]), but they require feeding labeled reagents to
model organisms, which makes multiple experiments cost-
ineffective.
There are advantages and disadvantages to both meta-
bolic and chemical modification-based labeling methods. For
SILAC, cells need to undergo multiple cell divisions in me-
dium containing stable isotope-labeled amino acids to
ensure sufficient isotope incorporation for reliable compar-
ison between cell states. For this reason, it is not practical to
apply SILAC to generate quantitative data from primary cells
or to compare tumor tissue specimens directly. Moreover,
culture conditions need to be carefully monitored to prevent
interconversion between arginine and proline, which could
negatively affect quantification accuracy. However, since cells
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Figure 2. Example workflow of the quantitative phosphotyrosine analysis experiment using iTRAQ labeling. Proteins are extracted from
four biological samples (cell lines, stimulation time points, tissue samples), modified and digested. For quantification, the resulting pep-
tides are labeled with iTRAQ reagent and combined. The mixture is then subjected to two steps of enrichment for tyrosine phosphorylated
peptides: IP with antiphosphotyrosine antibodies and IMAC. Phosphorylated peptides eluted from the IMAC column are analyzed by LC-
MS/MS, typically on a quadrupole TOF mass spectrometer. Each MS/MS spectrum contains both sequence-specific fragmentation events
for identification of the peptide and phosphorylation site as well as the low-mass iTRAQ marker ions to quantify phosphorylation across
the four samples. iTRAQ quantification is normalized to the supernatant to eliminate variation resulting from the preparation process.
can be mixed prior to cell lysis and sample processing,
quantification error associated with differences in these steps
can be avoided, potentially leading to higher accuracy. By
comparison, postextraction methods permit quantitative
analysis of a broader variety of samples, including animal
tissues and human tumors, providing the opportunity to
follow in vivo changes between healthy and diseased states,
which in turn can lead to the discovery of new drug targets.
Since labeling typically occurs following enzymatic diges-
tion, sample handling needs to be carefully controlled to
minimize variation introduced prior to mixing differentially
labeled samples.
For many applications, quantification relative to an arbi-
trary state is not sufficient, and absolute quantification is
desired. Typically, absolute quantification would have
required the chemical synthesis of heavy-isotope coded pep-
tides [35] to be added to the sample as internal standards.
Recently, however, such peptides can be biologically expres-
sed using the method (named QconCAT) introduced by Pratt
et al. [36, 37], in which Escherichia coli is transfected with a
modified gene containing the peptide of interest. The trans-
fected E. coli is cultured in a medium containing heavy lysine
and arginine and the protein is digested following purifica-
tion, yielding the desired peptide, which can then be added to
the sample. A recent review by Mirzaei et al. [38] summarizes
the current techniques for production of isotope-labeled
peptide standards.
Label-free quantification may be employed as a less
expensive alternative. These analyses are typically performed
either through direct comparison of two samples analyzed
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on the same platform, or by spiking the sample with stand-
ard peptides and quantifying in reference to these standards
[39-41]. Unfortunately, label-free quantification does not
provide the multiplex advantage associated with SILAC or
chemical modification (e.g., iTRAQ), and therefore requires a
separate MS analysis for each sample. Moreover, label-free
analysis tends to have greater quantification error compared
to analysis of stable isotope-labeled samples, due to incon-
sistent sample processing and chromatography across mul-
tiple analyses.
In the near future, MS-based proteomics should be
increasingly focused on absolute quantification of protein
expression level and stoichiometry of major PTMs. This
information will make it feasible to directly compare data
between experiments, conditions, and laboratories. More-
over, absolute quantification will enable the development of
more complex, kinetic computational models describing the
biological systems in much greater detail.
5 Instrument choice
As with all MS, optimal instrumentation for phosphopro-
teomic analysis is defined by the application. For instance, in
the case of global phosphoproteomics, instrument choice
may be influenced by the facile neutral loss of phosphoric
acid (98 Da) from serine and threonine phosphorylation,
often resulting in uninterpretable MS/MS spectra. To cir-
cumvent this problem, with a quadrupole ion trap (IT) it is
possible to perform MS3 on the neutral loss peak from the
www.proteomics-journal.com
Proteomics 2008, 8, 4433-4443
W
A024SYN
'0 Y
id
4438 A. Nita-Lazar et al-
MS/MS spectrum; this strategy has been successfully imple-
mented for several large-scale phosphoproteomic studies
[42]. The facile neutral loss problem may also be addressed
by using a quadrupole TOF instrument, as the intensity of
the neutral loss peak is diminished by multiple collisions in a
high-pressure quadrupole, yielding an increase in sequence-
specific fragmentation and improved phosphopeptide iden-
tification. More recently, electron capture dissociation (ECD)
[43] and, especially, electron transfer dissociation (ETD) [44]
have been demonstrated to be particularly useful for the
analysis of labile PTMs including serine and threonine
phosphorylation, providing good sequence coverage even for
large peptides and proteins.
Compared to serine or threonine phosphorylation, the
phosphate attached to tyrosine is relatively stable and usually
does not produce a neutral loss in MS/MS mode, although
loss of 80 Da may be seen from some tyrosine phosphoryl-
ated peptides. In fact, MS/MS spectra of tyrosine phospho-
rylated peptides tend to resemble nonphosphorylated pep-
tides, although fragmentation N- and C-terminal to phos-
photyrosine typically produces a characteristic immonium
ion of m/z 216.0426. Since this fragment ion is specific to
tyrosine phosphorylation, precursor ion scanning coupled
with subsequent MS/MS analysis of the selected precursor
ions has been used to identify these pTyr-containing peptides
from complex mixtures.
Instrument choice is further affected by the chosen
quantification method. SILAC experiments require high
resolution and high mass accuracy because the number of
species in the MS spectra are doubled (or tripled), leading to
increased complexity and increased frequency of overlapping
peaks. Although many of the initial SILAC experiments were
analyzed on a quadrupole TOF instrument, most of these
studies are now conducted on instruments with quadrupole
IT fragmentation and Fourier-transform based detection
(e.g., LTQ-FTMS or LTQ-Orbitrap) due to increased MS/MS
acquisition speed in the IT and increased MS acquisition
mass accuracy and resolution in the FT mass analyzer.
Choice of instrumentation for iTRAQ-based quantification is
more restrictive due to the low m/z ratio of the iTRAQ
marker ions. Quadrupole IT instruments have traditionally
not performed well for these experiments because fragmen-
tation in a quadrupole IT is typically performed at a Q-value
of 0.25-0.3, leading to loss of the low mass region of the MS/
MS spectrum. The hybrid quadrupole TOF mass spectrome-
ter has been the instrument of choice for iTRAQ-based
quantitative phosphoproteomic analyses due to the high res-
olution and mass accuracy (low ppm range) in both MS and
MS/MS mode, providing accurate detection of the charge
state and unambiguous assignment of the monoisotopic
mass. Importantly, high-resolution MS/MS spectra obtained
on this instrument have improved quantification accuracy by
separating iTRAQ marker ions from contaminant ions at the
same nominal m/z ratio [45]. The recent development of C-
Trap-based fragmentation on the LTQ-Orbitrap now enables
triple quadrupole-like fragmentation and high resolution,
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high mass accuracy detection in the orbitrap mass analyzer,
potentially providing a viable alternative to quadrupole TOF
instruments for iTRAQ-based quantification of phosphoryl-
ated peptides [46].
Given the large array of available enrichment and quan-
tification techniques and the possible combinations of these
approaches with various types of MS, it is worth reviewing
how these options have been implemented to interrogate the
phosphoproteome.
6 Phosphoproteomics in the EGFR
network
In canonical growth factor signaling, stimulation of cell sur-
face receptors first triggers activation of the receptor and
subsequently transmits the signal to a large number of
intracellular effecter molecules. The EGFR network is one of
the most extensively studied areas of signal transduction,
and the one which best exemplifies oncogenic aberrations in
cellular signaling [47]. EGFR is a member of ErbB family of
RTKs which comprises four receptors (EGFR, HER2, HER3,
and HER4) and 13 polypeptide ligands, each of which con-
tains a conserved epidermal growth factor (EGF) domain.
This complex signaling network has been one of the primary
targets for phosphoproteomic analysis. In fact, one of the
first studies to address quantitative dynamics of phosphoryl-
ation at the network level was performed in the EGFR sys-
tem. In this study, a monoclonal antiphosphotyrosine anti-
body was used to immunoprecipitate SILAC-labeled tyrosine
phosphorylated proteins and their binding partners. These
proteins were enzymatically digested to peptides and ana-
lyzed by LC-MS/MS, resulting in the identification of -80
signaling proteins, including many known EGFR substrates
and several novel effectors [9]. The relative intensity of
SILAC-labeled peptides was used to quantify temporal
dynamics within the network following EGF stimulation of
HeLa cells. However, since enrichment for tyrosine phos-
phorylation was performed at the protein level and enzy-
matic digestion produces a broad variety of tryptic peptides,
most of which represent nonphosphorylated sections of the
immunoprecipitated proteins, very few phosphorylation
sites were identified in this study, and therefore much of the
key signaling information is missing. In fact, since phos-
phorylation often happens at multiple tyrosine residues
within a single protein, and different phosphorylation sites
on a single protein are often differentially regulated with in-
dividual functions, quantification of each phosphorylation
site in the global signaling network is critically important.
To address the need for site-specific quantification,
Zhang et al. [26] performed time-resolved temporal analysis
of EGFR signaling network by quantitative MS using iTRAQ.
In this study, proteins from whole cell lysate were proteo-
lyzed to peptides and labeled with iTRAQ prior to mixing.
Tyrosine phosphorylated tryptic peptides were then en-
riched, first by IP with an antiphosphotyrosine antibody, and
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then by IMAC to eliminate nonspecifically retained
nonphosphorylated peptides. As a result, 104 tyrosine phos-
phorylation sites from 76 proteins were identified with tem-
poral phosphorylation proffles at four time points of EGF
stimulation. Site specific monitoring of protein phosphoryl-
ation in this study provided explicit detail regarding the reg-
ulation of proteins within the signaling network, including
differential regulation of multiple sites on given proteins,
and identification of phosphorylation "modules", clusters of
sites with selfsimilar temporal profiles.
Peptide IP has now been successfully implemented in a
variety of phosphoproteomic studies, including a recent
large scale analysis to identify phosphotyrosine signaling
networks in lung cancer cell lines and tumors [48]. In this
study, oncogenic tyrosine kinase signaling was characterized
by analysis of tyrosine phosphorylation in 41 nonsmall cell
lung cancer (NSCLC) cell lines and over 150 NSCLC tumors,
resulting in the identification of a total of 4551 sites of tyro-
sine phosphorylation on greater than 2700 different proteins.
Bioinformatic analysis of the dataset identified a subset of
NSCLC tumors and cell lines exhibiting high tyrosine phos-
phorylation, possibly due to the presence of abnormally acti-
vated or overexpressed tyrosine kinases. Potential "driver"
tyrosine kinases were identified by a ranking process to
identify unusually high levels of tyrosine kinase activity in a
subgroup of patients. Among the 18 tumors with highest
EGFR rank, nine tumors were confirmed to have an activat-
ing mutation in the kinase domain. Based on this success, a
similar approach was used to identify other candidate driver
tyrosine kinases in the remaining tumors, including the
fusion tyrosine kinase EML4-ALK, as also recently reported
by Soda et al. [49]. This example demonstrates that MS-based
phosphoproteomic discovery capabilities are highly com-
plementary to the genomic cDNA screening technology that
was used to originally identify this transforming fusion tyro-
sine kinase.
7 Global phosphoproteomics
With advances in MS and phosphopeptide separation meth-
odologies, the scale of global phosphoproteomic studies has
increased significantly since the first large-scale global anal-
ysis of the yeast phosphoproteome [14] only 5 years ago. For
instance, Olsen et al. [50] recently quantified global phos-
phorylation changes in EGF stimulated HeLa cells by com-
bining SILAC for relative quantitation with SCX and TiO 2
chromatography for phosphopeptide enrichment. Enriched
phosphopeptides were analyzed by more than 100 LC-MS/
MS runs to identify over 6600 phosphorylation sites on 2240
proteins with their annotated subcellular (nuclear vs. cyto-
solic) localization. This information represents the largest
global phosphorylation dataset available to date for the EGFR
signaling network, and covers a broad spectrum of phos-
phorylation events, from EGFR autophosphorylation to
phosphorylation of terminal effector molecules such as
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transcription factors. However, even this dataset is still far
from comprehensive, as many well characterized phospho-
rylation sites were not identified in this analysis. For
instance, the low number of pTyr sites (103) in the dataset is
likely due to the large dynamic range associated with simul-
taneous analysis of serine, threonine, and tyrosine phospho-
rylation. Given the large number of previously uncharacter-
ized phosphorylation sites and the massive size of this data-
set, extraction of biological hypotheses is not trivial.
However, it is likely that improved functional characteriza-
tion of the EGFR signaling network may arise from linking
this dataset to other complementary datasets [51] (e.g., Fried-
man and Perrimon's work RNAi-based screening to identify
components in the RTK-Erk network [52]).
8 Reproducibility of phosphoproteomics
One ofthe principal limitations with each of the above studies
has been the irreproducibility of MS-based data, such that
replicate analyses ofthe same sample (or analysis of biological
replicates) will typically identify only 60-70% of the same
phosphorylation sites. Much of this irreproducibility stems
from operating the mass spectrometer in a nonbiased "dis-
covery" mode, in which the instrument continuously repeats
a cycle consisting of a full-scan mass spectrum, followed by
fragmentation of a certain number of the most abundant
peaks for peptide and phosphorylation site identification. This
mode enables identification of novel phosphorylation sites,
but the semiautomated peak selection process is inherently
irreproducible (see, for example, a study of peptide/protein
identification reproducibility by MS [53]), making it difficult
to directly compare multiple datasets. Recently we have
developed an approach combining "discovery" mode analysis
of selected biological samples with high reproducibility mul-
tiple reaction monitoring (MRM)-based "monitoring" mode
for quantification of hundreds of selected phosphorylated
peptides [45]. This method was applied to investigate the
temporal dynamics of 226 phosphorylation sites at seven time
points of EGF stimulation of HMECs. Because preselected
phosphopeptides are specifically monitored in MRM mode,
the number of peptides reproducibly identified from four
replicates increased from 34% in discovery mode to 88% in
monitoring mode. This combined method should be applica-
ble to a variety of biological systems, and will enable repro-
ducible network-wide quantification of cell perturbation
effects across a broad variety of stimulation conditions.
9 Phosphoproteomics and systems
biology
Computational and systems biology approaches have
become increasingly important in the analysis of phospho-
proteomic data. To provide higher meaning to the data,
quantification of both the phosphorylation network and the
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corresponding biological response must be collected. Bioin-
formatics and mathematical modeling can then be applied to
build hypotheses connecting phosphorylation information to
cellular phenotypes. In the past, identification of key ele-
ments in signaling networks has largely been accomplished
in a subjective way through the manual comparison of fold -
change phosphorylation and cell behavior. Recently, mathe-
matical modeling methods such as partial least squares
regressions (PLSR) have been implemented to objectively
correlate phosphoproteomic data with cellular response to
stimulation. For instance, Wolf-Yadlin [25] et al. and Kumar et
at. [54] applied PLSR to the quantitative MS data describing
the effects of HER2 overexpression on phosphotyrosine sig-
naling in HMECs stimulated by EGF or heregulin (HRG).
Cell migration and proliferation were collected under the
same conditions and PLSR was used to integrate the data
types. The final model described a set of signaling molecules
that are most relevant for the changes in migration induced
by HER2 overexpression. This type of modeling can provide
insight into the functionality of unknown proteins, which
can be further tested by biological experiments.
As described above, the value of phosphoproteomic
datasets significantly increases when these data are used to
generate hypotheses as to the function of selected phospho-
rylation sites, and even more when these hypotheses are
experimentally validated. For instance, Kratchmarova et at.
[55] interrogated tyrosine-phosphorylation mediated signal-
ing networks following EGF or PDGF stimulation of mesen-
chymal stem cells. Interestingly, although most of the net-
work responded similarly to these two stimulations, activa-
tion of the P13K pathway was exclusive to PDGF stimulation.
Since EGF stimulation of these cells drives osteoblast differ-
entiation, the authors hypothesized that PDGFR-associated
P13K activation could be key to controlling biological re-
sponse to differential growth factor stimulation. Indeed, this
hypothesis was validated by small molecule inhibition of
P13K followed by PDGF stimulation to drive ostoblast differ-
entiation.
Another example of biological validation of MS-based
phosphoproteomic data was provided recently by Huang et
al. [56] in the quantitative phosphoproteomic analysis of the
EGFRvIII signaling pathways in U87MG glioblastoma cell
lines. Clustering of phosphorylation data identified pre-
viously unknown crosstalk between EGFRvIII and c-Met, a
receptor tyrosine kinase that is well known to drive malig-
nancy in various cancers. Since EGFRvIII and c-Met may
signal cooperatively to drive tumor growth, U87GM cells
expressing EGFRvIII were treated with the EGFR kinase in-
hibitor AG1478 and the c-Met inhibitor PHA665752. Either
compound alone had minimal cytotoxic effect, but the com-
bination of the two compounds significantly increased cyto-
toxicity at lower doses, indicating that EGFRvIII utilizes
other receptor tyrosine kinases to potentiate oncogenic sig-
naling. This finding has recently been corroborated through
the analysis of glioblastoma cell lines and tumors using
antiphosphotyrosine antibody arrays [57].
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10 Phosphoproteomics and drug
development
As described above, quantitative MS-based phosphopro-
teomics has been applied to identify oncogenic kinases
which may serve as potential drug targets. To validate this
hypothesis, cells are often treated with selected kinase in-
hibitors with the goal of altering cellular phenotype, but it is
often difficult to establish whether the effect was due to on-
or off-target effects of the compound. In order to determine
the mechanism of action, it may be necessary to quantify the
specificity of the inhibitor, a nontrivial task. To address this
challenge, Bantscheff et al. [58] developed a kinase capturing
bead ("Kinobead") consisting of multiple immobilized broad-
selectivity kinase inhibitors. On application to cell lysate, a
large number of kinases (and other purine-binding proteins)
are retained on the Kinobeads due to the interaction with the
kinase inhibitors. To obtain a quantitative target profile of a
selected compound, cells or cell lysate are treated with the
compound at varying concentrations prior to affinity isola-
tion with the Kinobead. Kinases inhibited by the selected
compound exhibit decreased binding to the Kinobead and
therefore yield decreased signal by quantitative (iTRAQ-
based) MS. Combining this approach with phosphorylation
analysis can yield a profile as to the phosphorylation status of
the kinases bound to the selected compound, potentially
identifying whether the compound binds to the active or
inactive isoform of the kinase. After establishing the speci-
ficity of the inhibitor, it will then be possible to regather
quantitative phosphoproteomic data to determine the effect
on the cell signaling network of inhibiting the selected tar-
gets of the inhibitor. The workflow for this approach is out-
lined schematically in Fig. 3. Following through this iterative
process, one could begin to build out downstream signaling
networks directly or indirectly affected by a selected kinase in
the context of various human pathologies.
11 Conclusions
What does the future hold for quantitative phosphopro-
teomics by MS? The field is in a rapid state of flux, including
new enrichment strategies, novel quantification reagents,
and new instrumentation. With each improvement it
becomes possible to identify and quantify increasing num-
bers of phosphorylation sites, digging deeper and deeper into
the elusive comprehensive phosphoproteome. However, as
many of the above applications demonstrate, size of the
dataset is not always the most important metric. Instead,
understanding the biological implications of many of the
phosphorylation sites is critical, since the ultimate goal of
most of these studies is to increase insight into cellular sig-
naling and biological control. Linking phosphorylation data
to other quantitative phenotypic endpoints is a crucial step in
this procedure, and one that has been often ignored in the
effort to gather larger data sets. Going forward, the combi-
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Figure 3. Signaling network analysis by mass spectrometry, drug-target discovery, and kinase inhibition. Mass spectrometry-based
phosphoproteomics is used to quantify signaling networks in various cell states resulting from multiple perturbations (e.g., cytokine
stimulation, RNAi, small molecule inhibitors). Computational modeling is used to link this information to quantitative phenotypic meas-
urements, thereby identifying key nodes In the signaling network. To validate this model, compounds are developed to target these nodes,
and the phenotypic effect is monitored. The specificity of the compounds can then be tested by the Kinobead assay to quantify on- and off-
target effects. Changes in the signaling network can then be quantified to establish kinase-substrate relationships given the established
targets of the compound.
nation of MS, phenotypic characterization, mathematical
modeling, and selected perturbations should provide rapid
advancement in our understanding of the complexities of
cellular signaling network, information that will enable the
development of better therapeutic agents with fewer off-tar-
get effects.
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1.4 Motivations
Tamoxifen treatment has been beneficial to millions of hormone receptor
positive breast cancer patients in the past several decades. The therapeutic
regimens are effective in prolonging the disease free survival period, cost-efficient,
and maintain high level of quality of life (QOL) for the majority of hormone receptor
positive breast cancer patients. It is regarded as the one of the best cancer
therapeutics available world-wide for women's health and welfare. However, even
such a successful therapeutic compound is not perfect. Due to the large number
of breast cancer patients who are put on the Tamoxifen treatment, any small
problem regarding its use could affect tremendous number of breast cancer patients
worldwide. In this regard, Tamoxifen resistance is a significant problem that
deteriorates breast cancer patients' QOL due to aggressive tumors that require
severe chemotherapies, giving breast cancer patients a higher degree of burden
and suffering.
In order to address the Tamoxifen resistance problem, we need to better
understand the disease mechanisms. Only through a better understanding of the
disease mechanisms is the better development of new therapeutics feasible.
laboratory has previously developed a quantitative chemical proteomic approach to
dissect phosphorylation signaling events in a system-wide fashion and has
successfully applied it to the study of the cancer model systems such as EGFR vill
signaling networks in human glioblastoma cell lines. In this thesis, I have applied
the phosphoproteomic analysis by mass spectrometry, which is the core of Forest
White Lab's technology, to the study of breast cancer cell line models with the
Tamoxifen resistance.
In order to study Tamoxifen resistance in breast cancer cell line models with
certain degrees of the clinical relevance, we have employed the classical breast
cancer cell line used for development of many current endocrine therapies. Such
models cell lines are modified to obtain two Tamoxifen resistant cell line models.
The two Tamoxifen resistant model cell lines are previously documented by multiple
groups and have been valuable cell line models to investigate the disease
mechanisms of the Tamoxifen resistance.
Although much work has been done in the past to elucidate genetic
changes that cause Tamoxifen resistance, the disease mechanisms that breast
Our
cancer cells employ to become anti-estrogen resistant are still not completely
understood. Furthermore, there are several important questions in which there is
a lack of consensus in the field, including if HER2 overexpression confers
Tamoxifen resistance in all ER*/HER2+ breast cancer patients, issues of ER's
non-genomic functions, and the cross-talk in ER*/HER2* systems.
The aim of this doctoral thesis is mainly three-fold. Firstly, the aim is to
employ quantitative phosphoproteomic analysis based on mass spectrometry to
gain a better understanding of the signaling changes due to exposure to Tamoxifen
treatment. Secondly, the aim is to compare the differences in signaling networks
between the Tamoxifen sensitive cells and the Tamoxifen resistant cells in order to
identify promising therapeutic targets. Thirdly, the aim is to test the hypotheses
generated from the quantitative phosphoproteomic analysis in model cell line
systems in order to validate the importance of proposed therapeutic targets.
This thesis incorporates the experimental results including development of
the Tamoxifen resistant cell lines from the Tamoxifen sensitive cell line, obtaining
quantitative phosphotyrosine data, the treatment of model cell lines with small
molecule inhibitors, phenotypic analyses such as migration assays and invasion
assays, rescue experiments with growth factor
mass-spec analysis of human breast tumor specimens. The analysis has revealed
interesting insights into network modulation and how the Tamoxifen resistant cells
fine-tune the phosphorylation levels of pro-survival and proliferative signals. In the
course of this thesis, I have established the power of quantitative
phosphoproteomics as a tool to dissect the therapeutic-resistance mechanisms by
analysing the phosphotyrosine mediated signaling network and as a means for
identifying molecular targets for pharmacological therapeutic interventions.
treatments, and finally the
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ll. Identification of therapeutic targets to revert
Tamoxifen resistance in breast cancer by
quantitative proteomic analyses of signaling
network
11.1 SUMMARY
Estrogen and estrogen receptor biology have been extensively studied in
the past fifty years, resulting in significant contributions to the development of breast
cancer therapeutics. Tamoxifen resistance is an unmet medical need affecting a
large number of patients with ER-positive breast cancer that have taken therapeutic
selective estrogen receptor modulators (SERMs). Non-genomic functions of
estrogen receptor (ER) provided many insights into the modulation of signaling
pathways by ER and potential mechanisms of Tamoxifen resistance. While the
non-genomic functions of ER affect the activities of kinases at various nodes, a
comprehensive map of signaling networks influenced by ER and changes within
these networks in disease settings such as Tamoxifen resistance are still lacking.
By plotting a global map of such a signaling network and identifying differences
between Tamoxifen sensitive and Tamoxifen resistant cell lines, one would be better
able to propose novel therapeutic candidates.
In this chapter, I describe the development of Tamoxifen resistant breast
cancer cell lines from a Tamoxifen sensitive cell line. The Tamoxifen sensitive
model is a parental MCF7 cell line, which is a classic model in studies of estrogen
biology. Two Tamoxifen resistant cell lines are described in this chapter. One of
the two Tamoxifen resistant cell lines is a HER2 overexpressing derivative of
parental MCF7. The second Tamoxifen resistant cell line is a derivative of parental
MCF7 cells which parental MCF7 were exposed to Tamoxifen for six months in
order for cells to acquire Tamoxifen resistance.
Next, I describe the designs and results of quantitative phosphoproteomic
analyses of tyrosine phosphorylation events, mainly focusing on signal transduction
downstream of HER2 tyrosine kinase and Src kinase. These analyses resulted in
the identification and quantification of 120 phosphorylation sites. MS analyses
highlighted several important differences in cell-specific aspects of Tamoxifen
treatment between Tamoxifen sensitive and Tamoxifen resistance cell line models.
For instance, network diagrams of each cell line showed upregulation of P13K-Akt
MEK-ERK1/2 pathways, and Src/FAK/AbI pathways in Tamoxifen
resistant cells.
phosphoproteomic
In addition to MCF7 cell line models, quantitative
analyses were extended to human primary breast tumor
samples. Two tumor samples were compared to study similarities and differences
pathways,
between in vivo and in vitro analyses. A tumor from a Tamoxifen treated patient
who suffered from recurrence was the first sample, and a tumor from a patient
before Tamoxifen treatment was the second sample. I found similarities between
data obtained from cell line analyses and primary tumors in that ERK1/2 and Src
phosphorylation sites increased their intensities in response to Tamoxifen.
In the last chapter, I describe phenotypic assays to illustrate how
quantitative phosphoproteomic analyses lead to the identification of effective
therapeutic candidates. We employed small molecule inhibitors, some of which
are FDA-approved, to validate our hypotheses developed from the MS analyses.
We hypothesized that PI3K-Akt pathways, MEK-ERK1/2 pathways, and
Src/FAK/AbI pathways are upregulated, play important roles, and are potential
therapeutic target in Tamoxifen resistant cells. Inhibition of these pathways
decreased the number of viable Tamoxifen resistant cells. The outcome of
inhibition experiments showed cell-context specific responses to each compound
treatment, with Src/Abl inhibition being the most effective treatment against both
Tamoxifen resistant cell line models. In addition, phosphoproteomic analyses from
a collaborative project on NOS inhibitor treatment, migration and invasion assays,
and preliminary results from experiments indicating potential IGF1-R/HER2
cross-talk are described.
This project was designed by Hideshiro Saito-Benz, Steven R. Tannenbaum,
and Forest M. White. The experimental procedure was conducted by Hideshiro
Saito-Benz, Kertikeya Pant, Kristen Naegle, Yi Wang, and Rachel Niehus.
11.2 MATERIALS and METHODS
11.2.1 Cell Culture, Cell line derivation.
MCF7 cell line is a breast epithelial adenocarcinoma cell line that expresses
ER, is responsive to estrogen for its growth, and has been a classical model to
study anti-estrogen treatment and resistance mechanisms. MCF7 were obtained
from American Type Culture Collection (ATCC) and all Tamoxifen
derivatives were established in the White laboratory, with an exception
MCF7-HER2 which was a kind gift from Dr. Jack Buesmans (Astra Zeneca).
MCF7 and their derivatives were cultured in the full growth media consisting of
red-free DMEM with 10% FBS and incubated in 95% air/5% CO2
atmosphere at 370C. MCF-TAM cell line was generated as previously described
(Knowlden et al., 2003). In brief, parental MCF7 cells were cultured in phenol
red-free DMEM with 10% charcoal-stripped FBS and 100nM 4-hydroxyltamoxifen
(4-OHT, Sigma) for six months. Approximately for the first four weeks, cell growth
As cells resumed slow growth after four weeks, cells were passed
resistant
phenol
remained static.
at 1:6 dilutions at 70% confluence for total six months.
developed by stably transfecting parental MCF7 with Flp-In plasmids included in the
Flp-Kit (Invitrogen).
11.2.2 Drug treatment for Viability Assay.
For cell viability assay, cells (1.Oxl 04/cm2) were seeded on six well plates in
triplicate for 24 hours before compound treatments. At each time point of
measurement, adherent cells were trypsinized and cell densities were counted on
ViCell Counter (Beckman Coulter) according to manufacturer's manual.
media with compounds were replenished every three days. P13K
The
inhibitors
(LY294002 and P1103) were purchased from CalBiochem, geldenamycin and
17AAG were purchased from Alexis Biochemical, and dasatinib was purchased
from LC Laboratories.
11.2.3 Peptide sample preparation, , and quantitative mass spectrometry.
MCF7-Flp cell lines are
For mass spectrometry analyses, all cells were seeded in the full growth
media at 1.0x1 04/cm2 on 15cm plates in biological duplicates. After 24 hours,
media was switched to the full growth media with 1OOnM 4-OHT or vehicle control.
Media and small molecule inhibitors were replenished every three days until cell
lyses. On the appropriate day, cells were lysed, processed and isotopically
labeled as previously described (Zhang et al., 2005). In brief, cells were lysed in
8M urea buffer with 100 mM sodium orthovanadate and proteins in cell lysate were
reduced with DTT and alkylated with iodoacetamide to block free thiols on cysteine
side chains. Samples were subjected to tryptic digestion and the
peptides were desalted on a C18 reverse phase cartridge (Millipore).
resulting
Peptides
were eluted with 1OmL of 25% acetonitrile, 0.1% acetic acid, and aliquoted in 500pg
fractions prior to lyophilization and storage at -80C until time of analysis.
11.2.4 iTRAQ labeling of peptides
Six samples were paired into two MS analyses combinations,
consisting of four samples that were covalently reacted with 4 isotopic labels of
each
iTRAQ. The first sample combination was labeled with iTRAQ reagent as follows:
iTRAQ 114: parental MCF7 with vehicle treatment, iTRAQ 115: parental with 15 day
4-OHT treatment, iTRAQ 116: MCF7-HER2 with vehicle treatment, and iTRAQ117:
MCF7-HER2 with 15 day 4-OHT treatment. The second sample combination was
labeled with iTRAQ reagent as follows: iTRAQ 114: MCF7-TAM with vehicle
treatment, iTRAQ 115: MCF7-TAM with 15 day 4-OHT treatment, iTRAQ 116:
MCF7-HER2 with vehicle treatment, and iTRAQ117: MCF7-HER2 with 15 day
4-OHT treatment.
11.2.5 Peptide Immunoprecipitation
After iTRAQ labeling, peptides were combined and subjected to peptide
immunoprecipitation as described (Zhang et al., 2005) with the following exceptions:
iTRAQ labeled peptides were incubated with 12pg of antiphosphotyrosine antibody
(P-Tyr-100, (Cell Signaling Technology)) and 12pg of antiphosphorylation antibody
4G10 (Millipore) in 200ug of immunoprecipitation buffer for 8 hours at 4C, followed
by incubation with 1 Oug of protein G Plus-agarose beads (Calbiochem) overnight.
112.6 Immobilized metal affinity chromatography (IMAC) and Mass
Spectrometry
Following elution from peptide immunoprecipitation, tyrosine
phosphorylated peptides were further enriched by immobilized metal affinity
chromatography (IMAC) to remove non-specific binding peptides resulting from
peptide immunoprecipitation (Moser and White, 2006). Peptides retained on the
IMAC column were eluted with 250mM sodium phosphate at pH8.0 and analyzed
by electrospray ionization liquid chromatography tandem MS on QSTAR XL Pro
Mass Spectrometer (Applied Biosystems) (Zhang et al., 2005). MS/MS spectra
were extracted, searched with Mascot (Matrix Science), and quantified with
ProQuant (Applied Biosystems). Phosphorylation sites and peptide sequence
assignments were validated by manual confirmation by assigning spectra of raw
MS/MS data. Area under the peak of iTRAQ reporter ions from phosphopeptides
were normalized with values from iTRAQ reporter ion peak areas of
non-phosphorylated peptides from high expression level proteins found in the
supernatant of the immunoprecipitation and corresponding to total peptide amount
for each condition. Each condition was normalized against the MCF7-HER2 cell
line with vehicle treatment to obtain relative percentages across all six conditions.
11.2.7 Preparation of Human Tumor Samples
Two human primary breast tumor samples (recurrent, or before treatment)
are received from Dr. Morag Park at McGill University in Canada. Each tumor was
approximately 100mg with pink color. Approximately 20mg of each tumor is cut by
surgical razor blades and remaining tumors were stored in -80C. The 20mg of
tumors were suspended in 1 ml of 8M urea, homogenized on ice, and processed for
tryptic digest in the same way as cell line lysate samples were processed. The
digested sample was passed through the fat-removal membrane (Waters) before
passed through SepPak C18 column. Recurrent tumor was labled with iTRAQ1 14,
and 116, and before-treatment tumor sample was labeled with iTRAQ115 and 117
to obtain standard errors and averages for every phpshorylation sites identified from
a single MS analysis.
11.2.8 ELISA measurement
ELISA measurements were conducted according to manufacturer's protocol
(Invitrogen).
duplicates.
In brief, cells were seeded at 1.0x1 04/cm 2 on 10cm plate in biological
After 24 hours, media was changed to the full growth media with
1OOnM 4-OHT or vehicle control. Cells were harvested at 70% confluence for
vehicle control, or after 15 days 4-OHT treatments, with denaturing cell extraction
buffer (Invitrogen) as recommended by manufacturer's protocols. Either 50pg,
25pg, or 10pg of protein lysates were used for detection of phosphoproteins and
total protein depending on abundance or proteins in each lysate in order to keep the
ELISA readings within a linear range of detection.
11.2.9 Bioinformatic Analysis
I created an aligned phosphopeptide background by expanding
sequence around every site of phosphorylation to +/-7 amino acids using the Entrez
the
Protein database. This yielded 129 aligned singly phosphorylated peptides.
then created a 4-OHT sensitive MCF7-HER2 foreground by choosing those
peptides that increased at least two-fold in the MCF7-HER2 cells in response to
4-OHT, which yielded 35 phosphopeptides and 42 singly phosphorylated aligned
peptides. We searched for enriched motifs within +/-5 amino acids of the oriented
phosphorylation site using a greedy search algorithm(Joughin et al., 2009). In
order to examine submotifs off of a parent branch in this algorithm, we required at
least 25% of the foreground matched the parent motif and with at least a
significance of 0.01, as judged by the hypergeometric test.
two final motifs with a p-value less than 0.01.
Motif analysis yielded
If we use Bonferroni correction to
adjust these scores for multiple hypothesis testing, the only motif that remains
significant is y.[EID]P with a p-value of 0.0058 and a corrected p-value of
0.064. Given Bonferroni is an overly severe correction due to interdependence of
the hypotheses tested, 0.064 is the upper bound on the significance of this motif,
but the motif is in fact likely to be more significant than this bound. To determine
the regulating kinase(s) responsible for enriched motifs we examined known linear
amino acid sequences in HPRD (Keshava Prasad et al., 2009) and utilized Scansite
We
kinase predictions (Obenauer et al., 2003).
11.2.10 NOS inhibitor treatments
Tamoxifen resistant cells (MCF7-HER2 and MCF7-TAM) were treated with
1) 100nM Tamoxifen alone, 2) 10OnM Tamoxifen and 1mM 1400W NOS inhibitor, 3)
1 OOnM Tamoxifen and 1 mM S-methylthiocitrulline (SMTC), and 4)
Tamoxifen and 0.3mM SMTC for 15 days. Cell culture media and compounds
were replenished every 3 days.
11.2.11 Growth factor treatments
Cells were seeded at 1.0x1 04/cm 2 on 10cm plate in biological duplicates.
After 24 hours, media was changed to the full growth media with vehicle control,
1 OOnM 4-OHT, with or without growth factors.
1 O0ng/ml. Media was replenished every three days.
EGF, HRG, IGF1 were dosed at
Parental MCF7 cells were
treated for nine days before counting viable cell numbers.
10OnM
MCF7-HER2 cells were
treated for six days before counting viable cell numbers.
11.2.12 Migration assay
All cells were seeded in the full growth media at 1.0x1 04/cm2 on 15cm
plates in biological duplicates. After 24 hours, media was switched to the full
growth media with 100nM 4-OHT or vehicle control and cultured for either six, nine
or fifteen days as the same conditions as mass spec samples were prepared.
Media and small molecule inhibitors were replenished every three days until cell
samples were tested for migration ability by Boyden chamber migration assay.
Parental MCF7, MCF7-HER2, and MCF7-TAM are grown for nine, six and nine
days respectively with vehicle treatment and seeded onto Boyden chambers.
Tamoxifen treated cells are grown for 15 days before seeded onto Boyden
chambers. Migration assay was conducted following the White lab migration
assay protocol. In brief, cells were directly seeded at 1.Ox1 05/cm2 in 1 00ul into
surface of Boyden chamber. Lower chamber was filled with the full growth media
with 10% FBS. Cells were undisturbed in cell culture incubator for 24, 48, and 72
hours, and stained with crystal violet cell stain solution. Cells on a top layer of
membrane were removed by cotton swabs, and numbers of cells on bottom layer of
Boyden chamber membrane were counted under a microscope. Three analytical
replicate wells were counted and experiments were repeated twice.
11.2.13 Invasion Assay
All cells were seeded in the full growth media at 1.0x1 04/cm2 on 15cm
plates in biological duplicates. After 24 hours, media was switched to the full
growth media with 100nM 4-OHT or vehicle control and cultured either six, nine or
fifteen days for same conditions as MS samples were prepared. Media and small
molecule inhibitors were replenished every three days until cell samples were
tested for migration ability by Boyden chambers filled with matrigels. Parental
MCF7, MCF7-HER2, and MCF7-TAM are grown for nine, six and nine days
respectively with vehicle treatment and seeded onto Boyden chambers. Similarly,
Tamoxifen treated cells are grown for 15 days before seeded onto Boyden
chambers. Invasion assay was conducted following the White lab migration assay
protocol. In brief, matrigel was diluted at 30 fold in serum free growth media, and
1 00ul diluted matrigel was spread on Boyden chamber prior to UV light exposure.
Cells were seeded at 1.Ox1 05/cm2 in 100ul into surface of Boyden chamber filled
with sterile matrigel. Cells were undisturbed in cell culture incubator for 24, 48,
and 72 hours, and stained with crystalviolet cell stain solution. Matrigel and cells
on a top layer of membrane were removed by cotton swabs, and numbers of cells
on bottom layer of Boyden chamber membrane were counted under a microscope.
Three analytical replicate wells were counted and experiments were repeated twice.
11.3 RESULTS
11.3.1 Development of acquired Tamoxifen resistant MCF7 (MCF7-TAM).
In order to obtain MCF7 cells that naturally developed resistance to
Tamoxifen, parental MCF7 cells had been continuously exposed to 100nM
4-hydroxyTamoxifen for six months in low estrogen media following method
described in Knowlden et al (Knowlden et al., 2003). This approach mimics clinical
conditions when patients are put on adjuvant Tamoxifen therapy after surgical
removal of primary tumor and develops Tamoxifen resistance or Tamoxifen as
prophylaxis for women with high risk of breast cancer who develops Tamoxifen
resistant breast tumors. Cells were seeded such that 100 mm plates became
approximately 25% confluent, and media were switched to DMEM with 10% CSFBS
supplemented with 1OOnM 4-hydroxyTamoxifen (4-OHT). Growth of cells slowed
down and resulted in growth arrest conditions for the first four weeks. During this
period, a significant number of cells died, presumably due to combinations of
1OOnM 4-hydroxyTamoxifen and low estrogen in the media. The growth of
remaining cell population stayed static over the first month.
growth rate gradually increased to a noticeable level and cells on a 100mm plate
reached to confluence at the end of third month. From this point cells on 100 mm
plates were continuously passaged in a same treatment for additional three months.
There were two noticeable morphological changes at early stages of Tamoxifen
treatment after the second month and late stage of Tamoxifen treatment at the sixth
month. After two months of exposure to 1OOnM Tamoxifen, cells showed
broadened morphology that was distinct from parental MCF7 (Figure 1).
After four weeks, a
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Figure 1. Images of parental MCF7 and MCF7-TAM under microscope. A).
parental MCF7 under confluent condition. 400x magnification. B) MCF7 cells
exposed to Tamoxifen for 2 months shows spread out cellular phenotype. 400x
magnification. C). parental MCF7 under confluent condition. 1 00x magnification. D)
MCF7 cells exposed to Tamoxifen for 6 months (MCF7-TAM) grows with tight
cellular density with close contact to each other. 1 00x magnification.
This broadened morphology was indicative of stressed cells presumably due to low
estrogen and presence of Tamoxifen. At the fifth and sixth months of low
Tamoxifen treatment, cells started to grow noticeably faster compared to the third
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month, and also showed distinct morphology compared to that of second-third
months or that of parental MCF7 (Figure 1 D). The cells grew in high area density,
and area occupied by a single cell became visually less than parental MCF7 cells.
When cell diameter observed during trypsinization, cell size did showed less than
10% changes in cell diameter (approximately 19pm (MCF7-TAM, six months)
compared to 20pm (parental MCF7) when counted Vi-Cell XR). Tightly packed
cells indicates that cell-cell contact proteins have been altered in order for cells to
tightly contact to each other. Although long-term treatment of parental MCF7 cells
with 100nM 4-OHT has previously been shown to result in increased EGFR/HER2
expression (Knowlden et al., 2003), MCF7-TAM cells generated in this study did not
demonstrate noticeable increase in HER2 expression (Figure 2A), and did not
decrease estrogen receptor (ER) expression (Figure 2B)
A
U.
iuW
cc~.
40 1U
C r*-
HER2
B
Parental MCF7-TAM
I ERa
beta-actin
Figure 2. Western blot for HER2 and ER. (A) Total protein expression level of
HER2 in parental MCF7, MCF7-TAM and MCF7-HER2 was compared by western
blot. parental MCF7 and MCF7-TAM expresses similar level of HER2, while
MCF7-HER2 express approximately 40 fold higher level of total HER2 protein.
p-actin was used to control for total protein loading. (B) Total protein expression
level of ER in parental MCF7 and MCF7-TAM. MCF7-TAM cells maintain ER
expression after 6 months of exposure to 1 OOnM 4-OHT.
11.3.2 Obtaining HER2 overexpressing MCF7
HER2 overexpressing MCF7 has been previously documented by several
groups to become Tamoxifen resistant in vivo (Benz et al., 1992; Shou et al., 2004).
While both Forest and I contacted the authors of the paper, we could not receive the
cell line clone. The reason was mainly due to the patent issue that restricted the
distribution of the MCF7-HER2 clone 18 described Benz et. al and Show et al(Benz
et al., 1992; Shou et al., 2004). The MCF7-HER2 clone 18 was patented under
Genentech and was restricted from distribution to both academic and industrial labs.
Because of inability to access the published MCF7 clone that overexpress HER2,
we decided to produce our own MCF7 cell line with HER2 overexpression
The Flp-In stable transfection system is the stable transfection methodology
which allows integration and expression of gene of interest in mammalian cells at a
specific genomic location (Figure 3).
1. Stably transfect to
obtain MCF7-FRT with
Zeocin selection
MCF7-FRT
2. Clone HER2 into
expression vector
3. Co-transfect with plasmid
expressing Flp recombinase &
select with hygromycin
4. Tes H MCF7-HER2
4. Test HER2 expression
Advantages:
1. Once MCF7-FRT is produced, second transfection is
mediated by Flp recombinase rather than relying on
random integration event
2. The integration event occurs at same location in the
genome, producing isogenic clones with same
expression level
3. Production of stable clone with different gene
expressing same level is feasible, allowing direct
comparison of effect of two genes
4. Production of multiple different clones with gene of
interests at preferred expression level is possible
Disadvantages
1. Must produce MCF7-FRT with classical stable
transfection method as Flp-In host MCF7-FRT is not
commercially available from Invitrogen
2. Selection with Zeocin is not as easy as as other
selection agent such as G418
3. Takes longer time than retroviral transfection followed
by FACS sorting based on reporter expression
Figure 3. FIp-In stable transfection system A) Overall scheme of transfection
steps in Flp-In stable transfection system. B) Advantages and disadvantages
compared to traditional stable transfection or retroviral transfection.
It was one of the latest stable-transfection methods that Invitrogen was
advertising around the time when we decided to produce MCF7-HER2. Amy
Nicholes was producing HER2 overexpressing LNCaP Prostate cell lines using
A
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Ftp-In system in the White Lab at the time I was going to make MCF7-HER2. The
system involves introduction of single or multiple Elp [ecombinase target (FRT)
site(s) into the genome of the parental MCF7 cells to create FIp-In ready host
MCF7-FRT cell line. An expression vector containing HER2 was then integrated
into the genome of the MCF7-FRT at the specific FRT location via Ftp
recombinase-mediated DNA recombination (O'Gorman et al., 1991). There are
multiple advantages of the Ftp-In stable transfection system compared to traditional
stable transfection or by retroviral transfection. The advantages and disadvantages
are summarized in Figure 3B. Once the Flp-In host cell line containing an
integrated FRT site has been created, subsequent generation of Ftp-In cell lines
expressing the genes of interest is rapid and efficient because integration is directed
by Flp recombinase rather than random integration event. In addition, the system
allows the generation of an isogenic stable cell line as the gene of interests is
integrated into the same site in the genome. This is useful when effects of two
genes are needed to be compared. For example, if effects of HER2 and
constitutively active spliced variant HER2 are assessed, it is desirable that
expression levels are kept at the same level. It is challenging to obtain such
clones by conventional methodologies, but theoretically FIp-In system allows to
produce two MCF7 derivatives that has integrated different genes at a same part of
host genome to derive the expression at same levels.
Successful stable integration of the linear plasmid and expression is
random and rare, which is estimated to occur in less than one in a million
transfected cells. Therefore optimizing the transfection condition was important
before starting the selection process with antibiotics. Similarly, as excessively high
antibiotic concentration can select out successfully transfected cells, determining
the lowest antibiotic concentration possible for selection was important so that all
untransfected cells are killed with antibiotics while only successfully transfected
cells survives. To identify a optimal condition, transfection with Lipofectamine2000
(Invitrogen) was tested with various ratio of Lipofectamine2000 to linearized plasmid
DNA to maximize a transfection efficiency while a minimizing toxicity. Among
Lipofectamine:DNA ratios tested between 1:0.5 and 1:5, the 1:2 ratio with 30pg
plasmid DNA was shown to yield maximal transfection efficiency with minimal
toxicity based on GFP expression of viable cells. To determine optimal antibiotic
concentration, MCF7 cells transfected with an empty vector was subjected to
selection with incremental concentration of Zeocin antibiotics from 10pg/ml to
800pg/ml (Invitrogen). An optimal Zeocin concentration to select MCF7
transfected with GFP vector was determined to be 25pg/ml, and this concentration
took approximately 10-12 days to kill approximately 80% of MCF7 transfected with
a control vector. To transfect the MCF7 with linearized pFRT//acZeo 100 mm plate
was brought to 50% confluent, and cells were transfected with Lipofectamine2000
at 1:2 ratio with 30ug linearized pFRT//acZeo plasmid or control vector pcDNA/GFP.
24 hours after the transfection, successful transfection was confirmed by GFP
expression in control cells. At this point, >70% confluent 100 mm plates were
subcultured at 1:4 into four 150 mm plates and cells were allowed to attach for 24
hours before the start of antibiotic selection. The resulting plates
approximately 20% confluent and selection with 25pg/ml Zeocin was started at 48
hours after the transfection. The media with 25pg/ml Zeocin was replenished
every two days to remove dead cells and to sustain antibiotic pressure. After 10
days of antibiotic selection, significantly more than expected number of cells looked
viable under microscope; this was most likely due to incomplete selection with
25pg/ml. Therefore, Zeocin concentration was increased to 50pg/ml for all 150
were
mm plates. However, significant changes were not observed in the next five days,
and therefore Zeocin concentration was increased again. Zeocin concentration
was increased to 100pg/ml in one third of the plates, and to 200pg/ml in another
one third of the plates, and to 400pg/ml in the last one third of the plate. After
another one week of selection, presence of viable cell colonies became clear
among almost empty plates (Figure 4A).
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Figure 4. MCF7-FRT clones (A) Viable MCF7-FRT colony under microscope after
Zeocin selection. 100x magnification (B) P-gal activity per protein concentration of
each clone. Note the higher the p-galactosidase activity, the higher the Zeocin
selection the colony can survive.
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The colonies were marked, isolated by clone isolation cylinder, and each colony
was transferred into 24 well plates to expand. From this point, cells in each well
were considered as individual clones. After reaching over 70% confluence, clones
in 24 wells were trypsinized, and all cells were transferred into 6 well plates to
further expand. Once 6 wells became >70% confluent (equivalent to 2x1 06 cells)
the cells were trypsinized and transferred into one 100 mm plate. Once a 100mm
plate were >70% confluent (15 x 106 cells), cells were subcultured at 1:3 into three
100 mm plates. Once three 100 mm plates were >70% confluent, cells from one of
three 100 mm plates were collected for the assay to measure P-galactosidase
activity resulting from stably integrated lacZeo gene, and cells from two other plates
were frozen down to save the clones. The protein concentration from the each
sample was also measured with a BCA assay. To determine the expression level of
p-galactosidase from stably integrated lacZeo gene (which will proportionally
correlate with HER2 expression level after HER2 integration), -galactosidase
activity from all clones was determined and normalized to MCF7-FRT clone ID
#26_3 which was the first clone isolated. B-galactosidase activity per protein
concentration of all clones is shown in Figure 4B. Notably, 0-galactosidase activity
level had approximately six fold difference between clones, and the Zeocin
selection concentration proportionally correlated with expression level. In the next
step, several selected clones will be co-transfected with pcDNA5/FRT/HER2 and
pOG44, and subjected for hygromycin selection to obtain MCF7-HER2 clones.
Once MCF7-HER2 clones are obtained, relative HER2 expression level are
measured by western blotting and MCF7-FLP Clone 6 (Med) and Clone 16 (High)
was successfully transfected to overexpress HER2, and expression level was 5x
and 1 Ox higher than the parental MCF7 (Figure 5).
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Figure 5. HER2 expression level of MCF7-HER2 via Flp-In relative to
MCF7-HER2 from Astra Zeneca. MCF7-FRT (med) with HER2 and MCF7-FRT
(high) with HER2 express 5x and 10x higher before HER2 transfection via Flp-In.
MCF7-HER2 from Astra Zeneca overexpress HER2 at much higher level (30-40x).
Advantages of MCF7-FLP clones with different expression level of reporter gene
expression is that transfection of other genes such as EGFR, IGFR-1 could be
studied at desired expression levels of each genes.
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While we derived HER2 overexpressing MCF7 via Fip-In system, we found
an access to HER2 overexpressing MCF7-HER2 from Astra Zeneca. We got
access to HER2 overexpressing MCF7 during the trip that Forest, Doug, Neil, Ale,
and Hide made trip to Astra Zeneca in July 2007. I was talking to one of the
researchers from the oncology group about my project, and they indicated that the
group internally obtained HER2 overexpressing MCF7 from retrovirally transfecting
the HER2 and selecting high overexpressing clones. MCF7-HER2 from Astra
Zeneca was a clone of MCF7 cells with 30-40x overexpression of HER2 based on
FACS selection with GFP as selection marker. Expression level of HER2 was
validated in the White lab by western blots, and results showed that HER2
expression was approximately 40 times higher than parental MCF7 (Figure 2A).
Because the original reports from Christopher Benz (Benz et al., 1992) used
MCF7-HER2 clone 18 which overespress HER2 at 42 times higher than parental
MCF7, we decided to use MCF7-HER2 from Astra Zeneca as a cell line of choice
for the project. MCF7-HER2 (med) and MCF7-HER2 (high) produced from Flp-In
study was saved for latter study as they could be used for other experiments such
as comparing signaling events in response to liner increase in kinaes expression
levels.
11.3.3 Growth Profiles of parental MCF7, MCF7-TAM, and MCF7-HER2.
Once all three cell lines are obtained, we decided to establish their
responsiveness to Tamoxifen. To determine the Tamoxifen sensitivity of parental
and derivative MCF7 cells, cell growth assays were performed in the absence and
of 4-OHT. As indicated in Figure 6, in the absence of 4-OHT,
MCF7-HER2 cells had significantly higher growth rate than parental MCF7 cells or
MCF7-TAM cells, presumably due to the pro-proliferative activating signal from
HER2, while under these same conditions parental MCF7 and MCF7-TAM grew at
approximately the same rate relative to each other.
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Figure 6. Growth profile of parental-MCF7, MCF7-TAM, and MCF7-HER2 in the
presence or absence of 1OOnM 4-OHT treatment. Average viable cell number
and standard deviation measured from three individual cell culture wells is plotted
as described in the methods. The plot is representative of at least three
independent biological replicates.
As expected, in the presence of 1 OOnM 4-OHT parental MCF7 cells
demonstrated a significantly decreased, almost static, growth rate, indicating a
strong sensitivity to Tamoxifen for this cell line. In stark contrast to parental MCF7
cells, the MCF7-TAM cell line was minimally responsive to 4-OHT treatment and
maintained a high growth rate in the presence of 4-OHT, indicating the almost
complete resistance of these cells to this concentration of 4-OHT. MCF7-HER2
cell growth rates were significantly diminished by exposure to 1OOnM 4-OHT,
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indicating a surprising sensitivity to Tamoxifen in this supposedly Tamoxifen
resistant model system. Although exposure to 1OOnM 4-OHT led to a significant
decrease in growth rate, MCF7-HER2 cells maintained a higher growth rate
compared to parental MCF7 cells under the same condition, and thereby
demonstrated an increased level of resistance relative to parental MCF7 cells.
Tamoxifen resistance of the MCF7-TAM and MCF7-HER2 cells extended to a higher
concentration of 4-OHT, as both cells demonstrated continued growth in the
presence of 1pM 4-OHT, while parental MCF7 growth was completely abrogated
under these same conditions (Figure 7).
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Figure 7. Growth profile of parental-MCF7, MCF7-TAM, and MCF7-HER2 in
1pM 4-OHT treatment. Similar to 1OOnM 4-OHT treatment, parental MCF7 is
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growth suppressed beyond 15 days. MCF7-TAM is not significantly growth
suppressed by 1pM 4-OHT treatment. MCF7-HER2 cells are affected by 4-OHT
treatment, but growth rate continues to be positive, similar to that shown for 1 OOnM
4-OHT exposure.
When three cell lines are grown in low-steroid media containing
charcoal-stripped FBS, parental MCF7 failed to grow, MCF7-HER2 maintained slow
grow rate, and MCF7-TAM grow most among all cell lines. These results indicates
that HER2 overexpression supplements the growth signal to make MCF7 cells
become less dependent on steroid media. On the other hand, MCF7-TAM cells
were steroid-independent for it growth, and became self-sufficient in growth
sustenance in steroid-depleted media condition. While MCF7-TAM maintaind
comparable ER expression levels to the parental MCF7, it was possible that
post-translational modification of the ER is significantly altered in MCF7-TAM such
that ligand-independent activation of ER occurred in these population (Shou et al.,
2004)
113.4 Tyrosine phosphorylation signaling network analyses of Tamoxifen
sensitive and resistant cells.
Although the estrogen receptor is best characterized as a nuclear receptor
and transcriptional regulator, it has also been proposed that this receptor have a
non-genomic role involving modulation of various signaling pathways (Bjornstrom
and Sjoberg, 2005). Since 4-OHT binds to the ER and thereby inhibits ER
activation, it is not surprising that this compound affects both estrogen-induced
transcriptional regulation and the non-genomic component of ER activity. To date
effects of 4-OHT on a ER non-genomic pathway has been shown only for selected
proteins in several pathways (Pedram et al., 2002), and a systems-level view of
4-OHT effects on the signaling network is still lacking. To address this issue we
have performed an unbiased, mass spectrometry-based, quantitative analysis
(Zhang et al., 2005) of tyrosine phosphorylation mediated signaling network
changes associated with 4-OHT treatment. Specifically, cell lysates were
generated from cell culture plates that had either reached 70% confluence in the
absence of 4-OHT, or had been treated with 100 nM 4-OHT for 15 days. As
described in Figure 8, tryptic peptides obtained from each of the six cell lysates
were isotopically labeled, with the MCF7-HER2 lysates serving as a common
normalization point for relative quantification across the six conditions.
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Figure 8. Schematic representation of the experimental approach for
MS-based quantitative proteomic analysis of tyrosine phosphorylation.
Following cell lysis and sample preparation, peptides from the six samples are
labeled with iTRAQ for relative quantification. MCF7-HER2 cells are used to
normalize the two experimental sets in order to obtain relative quantification across
all six samples. A representative MS/MS spectrum and iTRAQ marker ion peaks for
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pY605 on phosphoinositide-3 kinase p853 regulatory subunit 2 (P13K R2 pY605) is
shown.
Following stable isotope labeling, peptides from the appropriate samples
were mixed and tyrosine phosphorylated peptides were isolated with a two-step
enrichment protocol consisting of immunoprecipitation with a mixture of pan-specific
anti-phosphotyrosine antibodies followed by enrichment of phosphorylated peptides
by immobilized metal affinity chromatography (IMAC), as described previously
(Zhang et al., 2005). Peptides retained on the IMAC column were eluted to a
reverse-phase liquid chromatography column and analyzed by liquid
chromatography tandem mass spectrometry (LC-MS/MS) on a quadrupole
time-of-flight mass spectrometer. In total, 120 tyrosine phosphorylated peptides
from 80 proteins were identified and quantified from analysis of biological replicates
of the six samples (Table 1). Data-dependent peak selection for tandem MS
fragmentation is known to introduce variability in the peptide identification and
quantification in any given analysis; here this variance resulted in 80 of the 120
peptides being quantified across all conditions, while 15 and 25 were quantified for
only four of the six conditions (Figure 9A).
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Figure 9. Results of MS-based quantitative proteomic analysis of tyrosine
phosphorylation. (A) Of the 120 tyrosine phosphorylation sites identified and
quantified in this analysis, 80 phosphorylation sites were quantified for all six
conditions, while 25 were quantified in only the MCF7-parental and MCF7-HER2
cells (Set 1), and 15 were quantified in only the MCF7-TAM and MCF7-HER2 cells
(Set 2). (B) Hierarchical clustering was performed to visualize the effects of 4-OHT
treatment on tyrosine phosphorylation network across the three cell lines. Cell
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context dependent changes are evident, as each of the cell lines displays a
significantly different response to 4-OHT exposure. Heat map scale is fold-change
relative to MCF7-HER2 control.
Data generated in this study indicate that exposure to 4-OHT affects
tyrosine phosphorylation levels of many proteins and kinases and that this effect is
strongly dependent on cellular context. For instance, as depicted in Figure 9B,
exposure of MCF7-HER2 cells to 100 nM 4-OHT resulted in an increase in many
tyrosine phosphorylation sites, while parental MCF7 cells displayed a much different
response to the same treatment, with multiple phosphorylation sites decreasing in
intensity while others displayed minimal change. MCF7-TAM cells are the most
resistant to Tamoxifen and had the smallest response to 4-OHT exposure, with most
sites demonstrating no change in phosphorylation, and only a select subset of
phosphorylation sites increasing in intensity with 4-OHT.
The complex, context-dependent response to 4-OHT treatment was
detected at both the network level and for individual proteins. To better visualize this
cell-specific differential response to 4-OHT, quantification of protein phosphorylation
changes in the canonical ErbB signaling network and downstream cell adhesion
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proteins are depicted in Figure 10-12.
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Figure 10. Schematic representation of the fold change in phosphorylation
level in the canonical ErbB and cell adhesion signaling networks in response
to 4-OHT treatment in MCF7-HER2. Note that many of the phosphorylation events
increase significantly in response to 4-OHT exposure. For each phosphorylation site,
the fold change in phosphorylation level relative to control treatment for each cell
line is represented by red (>2-fold change), orange (1.25-2.00 fold change), green
(0.75-1.25 fold change), or blue (<0.5-fold change).
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As can be seen in these panels, five tyrosine phosphorylation sites were
identified and quantified on the HER2 receptor tyrosine kinase. Of these five sites,
three (pY1005, pY1236, and pY1248) demonstrated an increase in phosphorylation
level, one (pY1127) was unchanged, and one (pY877) decreased
phosphorylation level following exposure of the MCF7-HER2 cells to 4-OHT (Figure
10 and Table 1). For HER2 pY1 248, the C-terminal docking sites for many adaptor
molecules, the basal phosphorylation level was -30 fold higher in MCF7-HER2 cells
compared to parental MCF7 and MCF7-TAM; in response to Tamoxifen treatment,
the phosphorylation level increased by 2-fold in the MCF7-HER2 cells,
previously reported (Shou et al., 2004), but remained unchanged or slightly
decreased in the parental MCF7 and MCF7-TAM cells (Figure 11-12, and Table 1).
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Figure 11. Schematic representation of the fold change in phosphorylation
level in the canonical ErbB and cell adhesion signaling networks in response
to 4-OHT treatment in parental MCF7. Note that many of the phosphorylation
events increase significantly in response to 4-OHT exposure in MCF7-HER2, while
most of the sites decrease in phosphorylation following exposure to 4-OHT in the
parental MCF7 cells. For each phosphorylation site, the fold change in
phosphorylation level relative to control treatment for each cell line is represented
by red (>2-fold change), orange (1.25-2.00 fold change), green (0.75-1.25 fold
change), or blue (<0.5-fold change).
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Figure 12. Schematic representation of the fold change in phosphorylation
level in the canonical ErbB and cell adhesion signaling networks in response
to 4-OHT treatment in MCF7-TAM. The MCF7-TAM cells display a more muted
response, with most sites being unaffected by 4-OHT exposure, and selected sites
increasing between 1.25 and 2-fold relative to the untreated MCF7-TAM cells. For
each phosphorylation site, the fold change in phosphorylation level relative to
control treatment for each cell line is represented by red (>2-fold change), orange
(1.25-2.00 fold change), green (0.75-1.25 fold change), or blue (<0.5-fold change).
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Phosphorylation levels for this site were also measured by ELISA,
confirming the observed increase in HER2 pY1248 in MCF7-HER2 after 4-OHT
treatment (Figure 13A). The relative increase in phosphorylation was not due to a
change in HER2 expression level, as the total HER2 level was not significantly
altered by exposure to 4-OHT (Figure 13B).
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Figure 13. Enzyme linked immunosorbant assay (ELISA) measurement of
HER2. (A) HER2 phosphotyrosine 1248 was quantified by ELISA in the three cell
lines in the presence and absence of 4-OHT. Quantification pattern on HER2
pY1248 from ELISA is similar to the relative quantification results from MS-based
phosphotyrosine level measurements. (B) As demonstrated by western blots in
Supplementary Figure 1A, ELISA quantification also shows that the total HER2
expression level is similar for parental MCF7 and MCF7-TAM cells, but is increased
-40x in the MCF7-HER2 cells.
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The cell context-specific 4-OHT response is further highlighted by HER2
pY1127, a site of unknown function, whose phosphorylation level increased
dramatically in the MCF7 parental and MCF7-TAM cell lines in response to 4-OHT
exposure, but was unchanged in the MCF7-HER2 cells. As figures clustering and
network figure indicate, similar signaling complexity is recapitulated throughout the
network. In order to understand how the complex regulation of these signaling
networks relates to Tamoxifen resistance, it is necessary to identify those
phosphorylation events that correlate most strongly with the primary phenotype of
interest, growth rate in the presence of 4-OHT.
1.3.5 Human primary tumor analysis.
In addition to Tamoxifen resistance cell line models, we extended
phosphoproteomic analyses of tyrosine phosphorylation events to primary human
tumors. We received two primary human breast tumor samples from Dr. Morag
Park at McGill University in Canada. These two tumors are selected from the
McGill Univeristy Hospital tissue bank, the largest tumor data banks in Canada.
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The first sample was from a patient who was diagnosed with ER'invasive ductal
carcinoma (IDC) in 1991. The standard therapeutic procedure for such patients in
1991 was to surgically remove breast tumors, then put patients on five years of
adjuvant Tamoxifen treatment. The first patient received the five years Tamoxifen
treatment until 1996, and adjuvant Tamoxifen treatments were completed at this
point. Unfortunately, this patient relapsed with grade 3' recurrent breast tumor
with ER+ and HER2* in 2000. The tumor sample was collected at the time of
recurrence in 2000, when patient was at age 72. The second primary tumor
sample was from a patient who was diagnosed as IDC with ER' and HER2' at
grade 3' and tumor sample was collected at the time of diagnosis in 1999, when the
patient was age at 77, before the start of adjuvant Tamoxifen treatments.
It would have been ideal to have the patient-matched samples. For
example, the first sample at the time of diagnosis in 1991 would be perfect to
compare changes between original and recurrent tumor samples. Unfortunately,
such patient-matched samples were not available from the tumor bank, and the
second tumor sample described above was chosen as the best histological match
to the first primary tumor. To a limited extent, these tumor pairs are analogous to
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the MCF7-HER2 cell lines with or without Tamoxifen treatment for 15 days because
both data sets are for ER*/HER2* samples with or without Tamoxifen treatment.
Both tumor samples were homogenized and processed to tryptic peptides
in the same way as cell lysates were processed for MS analyses. Detection of
tyrosine phosphorylation sites from the tumor xenografts has been difficult due to
low levels of phosphotyrosine (Paul Huang, personal communication), and similarly,
detection of phosphotyrosine from primary tumor samples was more difficult than
detection from cell line samples. This is primary due to the heterogeneity of
human tissues, in which stromal cells and fibroblasts are present in addition to
cancer cells. In order to maximize the level of phosphotyrosine injected into mass
spectrometer, the amount of peptides that are labeled with iTRAQ reagents were
doubled, and analytical replicates were conducted within one MS analysis.
Peptides from the recurrent tumor sample were labeled with iTRAQ 114 and 116,
whereas peptides from the before-treatment sample were labeled with iTRAQ 115
and 117, enabling the calculation of average and standard error for all of the
phosphorylation sites from a single MS analysis.
Forty tyrosine phosphorylation sites were identified and quantified, enabling
comparisons between a recurrence sample and a before-treatment sample (Figure
14). These 40 phosphorylation sites include sites from many signaling molecules,
kinases, and phosphatases such as STAT2, PKC6, P13K regulatory subunit 1,
WASP, DYRK1, FRK, FYN, HER2, HER3, PTPRA, FAK, SHIP2, MAPKs, and SHC.
Intriguingly, the levels of phosphorylation from the majority of phosphorylation sites
were higher in the recurrent tumor sample, and half of phosphorylation sites were
more than two fold higher in the recurrent tumor sample. Importantly,
phosphorylation sites on many tyrosine kinases were over two fold higher in the
recurrent tumor sample including SRC family kinases, HER2, HER3, and FAK. In
addition to tyrosine kinases, four MAP Kinases (ERK1, ERK2, p38a, and p386)
were phosphorylated between four- and six-fold higher in a recurrent sample.
Trends in the phosphorylation of SRC/FAK and ERK 1/2 were similar to those
observed in phosphoproteomic analyses from MCF7-HER2 cell line models with
Tamoxifen treatment. SRC/FAK and ERK1/2 pathways may have higher activities in
a recurrent tumor compared to a before-treatment tumor in a similar manner that
Tamoxifen treated MCF7-HER2 may have higher SRC/FAK and ERK1/2 pathways
than untreated MCF7-HER2.
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Figure 14. Phosphoproteomic analysis of human primary breast tumor. Forty
tyrosine phosphorylation sites are identified. Fold changes between two primary
tumor samples are shown (a sample from the patient with recurrent tumor over a
sample from patient before Tamoxifen treatment. Note that HER2, Src, and FAK
tyrosine kinases and four MAP Kinases (ERK1, ERK2, p38a, p386) were highly
phosphorylated in a recurrent sample in a consistent manner as in results from
MCF7-HER2.
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113.6 P13K p85,8 R2 pY605 correlates with Akt pS473 levels and is highly
phosphorylated in Tamoxifen resistant cells.
To identify those sites correlated with cell growth rate in the presence and
absence of 4-OHT, we first checked phosphorylation levels on proteins known to be
associated with cell survival/anti-apoptosis signaling. Notably, pY605 on
phosphoinositide-3 kinase p850 regulatory subunit 2 (P13K p8501 R2) exhibited a
60% decrease in phosphorylation in parental MCF7, whereas the same site
increased by -70% and -100% in MCF7-HER2 and MCF7-TAM, respectively, in
response to 100 nM 4-OHT exposure (Figure 15). Although the function of the
pY605 site is not known, a motif characterized by the surrounding amino acid
sequence matches closely to the motif established for binding to the SH2 domain of
the P13K p85P regulatory subunit 1 (Scansite score=0.142) (Obenauer et al., 2003).
Interaction between the two P13K p85P regulatory subunits is a prerequisite for
recruitment of P13K p11 Oa catalytic subunit which fully activates the trimetric class I
P13K (Neri et al., 2002). P13K activation increases phosphatidylinositol
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3,4
bisphosphate (Ptdlns(3,4)P2)
(Ptdins(3,4,5)P3) in the cellular membrane leading to recruitment and activation of
Akt/PKB, which results in propagation of pro-survival signals. Based on the
increased phosphorylation of P13K p850 R2 pY605, and the potential role for this
site in mediating the interaction with P13K p85B R1, we hypothesized that the
PI3K-Akt pathway may be differentially regulated between Tamoxifen sensitive
(parental MCF7) and resistant (MCF7-HER2 and MCF7-TAM) cells,
activation providing a key pro-survival signal in the Tamoxifen resistant cell lines
treated with 4-OHT. To test the correlation between P13K p850 R2 pY605 and Akt
activation, Akt pS473, a surrogate for Akt activity, and total Akt were quantified by
ELISA (Figure 15B). While total Akt expression was essentially unchanged across
the three cell lines, Akt pS473 increased strongly in MCF7-HER2 and MCF7-TAM,
and decreased slightly in parental MCF7 with 4-OHT treatment, correlating in trend,
if not magnitude, with P13K p85P R2 pY605. It is likely that the difference in
magnitude between these signals may be due to other components of this signaling
module, including PTEN, the lipid phosphatase
Ptdins(3,4,5)P3.
regulating accumulation
We have recently found that PTEN S-nitrosation levels are
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with Akt
3,4,5-tri phosp hateand phosphatidylinositol
increased in MCF7-TAM cells following 4-OHT exposure (data not shown),
potentially decreasing the activity of this phosphatase and thereby amplifying the
pro-survival P13K-mediated Akt activation in the MCF7-TAM cells treated with
4-OHT.
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Figure 15. PI3K-Akt pathway activation and inhibition results. (A)
Phosphorylation of pY605 on phosphoinositide-3 kinase p85P regulatory subunit 2
(P13K p85P R2) increases in response to 4-OHT exposure in the Tamoxifen
resistant MCF7-TAM and MCF7-HER2 cells, but decreases in the Tamoxifen
sensitive MCF7-parental cells. (B) P13K p85p R2 pY605 phosphorylation correlates
with Akt phosphoserine 473, as measured by ELISA. (C) Change in
phosphorylation is not associated with change in protein expression level, as
quantified by ELISA measurement of total Akt expression level. (D) Schematic
representation of the small molecule inhibitor strategy for P13K inhibition. (E)
Individual or combinatory treatment of Tamoxifen resistant cell lines with Tamoxifen
and small molecules targeting P13K pathway. Note that either of the P13K
inhibitors, when combined with 4-OHT, has a much greater effect on the
MCF7-HER2 cells relative to the MCF7-TAM cells.
11.3.7 P13K inhibition in the presence of Tamoxifen decreases growth rate of
Tamoxifen resistant cells.
To determine the functional consequence of increased P13K/Akt pathway
activation in the Tamoxifen resistant MCF7-HER2 and MCF7-TAM cells treated with
4-OHT, small-molecule inhibitors targeting P13K (LY294002, a P13K inhibitor known
to target all classes of P13K, and P1103, a P13K/mTOR dual-specificity inhibitor(Fan
et al., 2006)) were used to modulate activity of this pathway in the presence and
absence of 4-OHT (Figure 15D). As a positive control for this study, gefitinib
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kinase inhibitor that has been shown to revert
Tamoxifen resistance in MCF7 cells overexpressing EGFR/HER2 (Shou et al.,
2004) was used to modulate
activation indirectly.
EGFR/HER2 activity, thereby decreasing P13K
The concentration of each small-molecule inhibitor was
titrated such that the inhibitor alone did not have an effect on cell growth rate in the
absence of 4-OHT.
growth for MCF7-TAM
MCF7-HER2.
As previously demonstrated, 4-OHT alone led to sustained cell
cells and sustained, but decreased, cell growth for
When cells were treated with the combination of 4-OHT and either
P13K inhibitor or gefitinib, a significant decrease in cell growth rate was seen for
MCF7-HER2 and MCF7-TAM cells. Specifically, addition of LY294002 or P1103 with
4-OHT significantly reduced cell growth rate compared to 4-OHT alone, whereas
addition of gefitinib with 4-OHT was more effective than either P13K inhibitor,
presumably due to the inhibition of other EGFR mediated pathways in addition to
the PI3K-Akt pathway. Co-treatment with 4-OHT and P13K inhibitors or gefitinib
was more effective in the MCF7-HER2 cells compared to the MCF7-TAM cells,
indicating the presence of a non-ErbB mediated Tamoxifen resistance mechanism
in the MCF7-TAM cells. Although co-treatment with any of the three compounds
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(Iressa, ZD1839), an EGFR
was moderately effective against MCF7-TAM, the effect of the co-treatment was not
sufficient to cease cell growth, and therefore these conditions may facilitate
selection of more resistant cells.
11.3.8 Erk1/2 phosphorylation pattern correlates with cell growth rate.
Since P13K inhibition was insufficient to arrest cell growth rate of the
MCF7-TAM cells exposed to 4-OHT, it was necessary to identify alternative targets
in the signaling network that might be more effective at reverting Tamoxifen
resistance of these cells. To this end, we observed that tyrosine phosphorylation
on the kinase activation loop of the Erk 1/2 mitogen-activated protein kinases
(MAPK) (Erk1 pY204 and Erk2 pY1 86) correlated with the phenotypic outcomes of
the Tamoxifen sensitive and resistance MCF7 (Figure 16).
119
ERK2 pY186
100-
50-.
+ - + - +
- Parental
- MCF7-HER2
M MCF7-TAM
+ Tamoxifen
RAF
PD98059H I(l
6-
4-
2-
0-
6-
4-
III
MCF7-HER2
MCF7-TAM
..ii
- - - - -- - - - - + Tamoxifen 1OonM
- - - - - - - ++++ ++++ PD98059 1OOnM
Figure 16. MEK-Erk1/2 pathway activation and inhibition results. (A)
Phosphorylation of pY204 or pY186 on Erk1 or Erk2, respectively, correlates with
cell growth rate for each of the cell lines with or without exposure to 4-OHT. (B)
Schematic representation of the small molecule inhibitor strategy for MEK/Erk
pathway inhibition. (C) Individual or combinatory treatment of tamoxifen resistant
cell lines with tamoxifen and PD98059, a small molecule kinase inhibitor of MEK.
Note that the combination of PD98059 and 4-OHT has a greater effect on the
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MCF7-TAM cells compared to the MCF7-HER2 cells.
Specifically, parental MCF7 and MCF7-TAM cells show similar levels of Erk1 pY204
and Erk2 pY1 86 in the absence of 4-OHT and grow at approximately the same rate,
while these levels are approximately 2-fold higher in the MCF7-HER2 cells that
grow significantly faster compared to the MCF7 or MCF7-TAM cells. The
correlation between phosphorylation and phenotype also applies
exposure to 1OOnM 4-OHT, as Erk1 pY204 and Erk2 pY186 decrease by 50% in
parental MCF7 and MCF7-HER2 cells that are strongly affected by 4-OHT, but do
not change significantly in MCF7-TAM cells, where the growth rate decreases only
slightly in response to the same treatment. Quantification by ELISA to measure
doubly phosphorylated Erkl/2 (pT202/pY204 and pT184/pY186) was in good
agreement with the MS data (Figure 17A), and the change in signal was not due to
alteration in the total protein expression level of these kinases, as determined by
quantitative ELISA (Figure 17B).
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Figure 17. Enzyme linked immunosorbant assay (ELISA) measurement of
ERK1/2. (A) Doubly phosphorylated ERK1 pT202/pY204 and ERK2 pT184/pY186
quantification pattern from ELISA is similar to the relative quantification results for
the singly (tyrosine) phosphorylated peptides of ERK1 and ERK2 identified and
quantified by MS-based phosphotyrosine measurements. (B) Total ERK1/2
expression level is relatively unchanged across the three cell lines and is unaffected
by 4-OHT exposure.
To test the functional consequence of Erkl/2 activation on Tamoxifen resistance in
these cells, we treated the cells with PD98059, a small molecule inhibitor of
MAPK/Erk kinase (MEK), the kinase regulating Erk activation (schematically
represented in Figure 16 B), and counted viable cells over a 20 day period following
treatment with PD98059 or control in the presence and absence of 4-OHT (Figure
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16C). As above, the concentration of PD98059 was adjusted such that minimal
effect was seen when cells were treated in the absence of 4-OHT. Upon addition
of 4-OHT in combination with PD98059, however, cell growth was greatly
decreased in both the MCF7-HER2 and MCF7-TAM cells, albeit to different levels.
Somewhat to our surprise, the cellular response to MEK/Erk pathway inhibition was
different than that seen for PI3K/Akt pathway inhibition, as the MCF7-HER2 cells
continued to grow at an appreciable rate upon MEK/Erk inhibition in the presence of
4-OHT, while cell growth was almost completely abrogated for the MCF7-TAM cells
under these conditions (Figure 16C). The combined results of PI3K/Akt and
MEK/Erk pathway inhibition indicate that the MCF7-HER2 cells may be more reliant
on the P13K pathway for survival and growth when exposed to 4-OHT, while the
MCF7-TAM cells are much more reliant on the MEK/Erk pathway to maintain their
Tamoxifen resistance. Neither inhibition strategy is sufficient to completely
abrogate cell growth rate of both cell line resistance models.
11.3.9 Increase in Src and Src family kinase substrate phosphorylation with
4-OHT exposure
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Although modulation of the P13K and Erk pathways was sufficient to reduce
Tamoxifen resistance in either the MCF7-HER2 or MCF7-TAM cells, the lack of a
single treatment option that displayed high efficacy in both resistance mechanisms
led us to further query the quantitative phosphorylation data to identify additional
4-OHT-induced phosphorylation changes that could represent
perturbation points to better modulate Tamoxifen resistance in both model cell lines.
Perhaps the most striking effects of MCF7-HER2 exposure to 4-OHT are the
phosphorylation changes induced on Src (note
phosphorylated peptide is identical for multiple Src family kinases, and therefore
quantification of this site likely represents the protein expression-weighted average
phosphorylation change on these Src family kinases expressed in these cells),
Focal Adhesion Kinase (FAK), and cell adhesion proteins, including several known
Src and FAK substrates (Figure 10 and Table 1). Although
phosphorylation of Src in response to 4-OHT treatment has been
increased
previously
reported in HER2-overexpressing Tamoxifen resistant MCF7 cells (Hiscox et al.,
2006), here the unbiased network analysis reveals the functional consequence of
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alternate
that the sequence of this
increased Src kinase activation through quantification of Src and FAK substrate
phosphorylation. Among the known Src substrates, FAK is a tyrosine kinase
known to localize at the focal adhesions and regulate cellular adhesion through
phosphorylation of a variety of membrane proximal proteins (Hanks and Polte,
1997); moreover, FAK pY576 is a Src-dependent phosphorylation site and is
indicative of FAK activity (Chaturvedi et al., 2007). Downstream of Src and FAK,
multiple tyrosine phosphorylation sites on adhesion, cytoskeletal, and adaptor
proteins increased phosphorylation in MCF7-HER2 cells exposed to 4-OHT (Figure
10). These hyperphosphorylated proteins include catenin 61 (pY224 and pY902),
catenin 62 (pY424 and pY499), paxillin (pY118), plakophilin 3 (pY390), plakophilin 4
(pY372, pY470, pY478, pY1139 and pY1168), cortactin (pY421 and Y446), and
SHB (pY114, pY246, pY268, pY297, pY336). Among these hyperphosphorylated
proteins, catenin 61, catenin 62, and cortactin are previously described as Src
kinase substrates (Mariner et al., 2001) (Huang et al., 1997). Paxillin Y118 has
been characterized as a FAK phosphorylation site; phosphorylation of this site has
been linked to the dissociation of paxillin from the focal adhesion protein complex,
resulting in detachment of cells from adhesion sites (Bellis et al., 1995). SHB
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phosphorylation also occurs in a Src-dependent manner and the SH2 domain of
SHB is known to interact with phosphorylated FAK (Holmqvist et al., 2003).
Although increased phosphorylation of the Src/FAK kinase and their substrates was
absent in parental MCF7 exposed to 4-OHT (Figure 11), a moderate increase in
phosphorylation of FAK and Src/FAK substrates was observed in MCF7-TAM upon
4-OHT exposure (Figure 12), indicating: (1) that increased Src/FAK activity may be
associated with Tamoxifen resistance in MCF7, and (2) increased HER2 expression
strongly potentiates Src/FAK kinase activation.
11.3. 10 Inhibition of Src/Ab activity reverts Tamoxifen resistance
To test the role of Src family kinases in mediating Tamoxifen resistance, the
Src/Abl dual-specificity inhibitor dasatinib (Lombardo et al., 2004) was used to
decrease Src activity in the presence and absence of 4-OHT (Figure 18). The
HSP90 inhibitors Geldenamycin and 17AAG were selected as a positive control for
this experiment, as these compounds have been reported to be effective against
Tamoxifen resistance in MCF7 cells (Beliakoff et al., 2003). In addition to their
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direct effect on HSP90, these compounds should significantly alter HSP90 client
proteins including HER2, ER, and Src (Whitesell and Lindquist, 2005), thereby
the network at multiple levels simultaneously. As above,
concentration of each small-molecule inhibitor was titrated to establish the
maximum concentration at which each inhibitor alone did not have an effect on cell
viability (100nM for dasatinib and 1OnM for geldenamycin and 17-AAG). Each
inhibitor was then tested as a single agent or added in the presence of 100nM
4-OHT and cells were counted at multiple points over 20 days (Figure 18 B). While
dasatinib, geldenamycin, or 17-AAG minimally affected cell growth when added to
cells in the absence of Tamoxifen, addition of any of the three compounds in the
presence of 1 OOnM 4-OHT completely abrogated cell growth rate, such that the total
number of cells was either unchanged or decreasing throughout the duration of the
experiment. It is worth noting that the effect of Src/Abl inhibition by dasatinib was
equally effective in reverting Tamoxifen resistance as the HSP90 inhibitors that were
included as the positive control in this experiment. More importantly, dasatinib
displayed good efficacy against both cell line models of Tamoxifen resistance, and
may therefore represent a clinically relevant therapeutic option for reverting
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Tamoxifen resistance regardless of HER2 expression status.
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Figure 18. Reversion of tamoxifen resistance by HSP90 or Src/AbI inhibition.
(A) Schematic representation of the targets of dasatinib, geldenamycin, and 17AAG.
Note that HSP90 is a chaperone protein with multiple additional client proteins that
are not represented in this schematic. (B) Combinatory treatment of tamoxifen
resistant cell lines with tamoxifen and dasatinib, geldenamycin, or 17AAG leads to a
significant decrease in the cell growth rate of the tamoxifen resistant cells, indicating
reversion of tamoxifen resistance under these conditions. Note that Src/Abl
inhibition works equally well against both cell lines, and has similar efficacy to the
positive control HSP90 inhibitors (geldenamycin and 17AAG).
11.3.11 Analyses of tyrosine phosphorylation events in response to NOS
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inhibitor treatments
One model for the basis of Tamoxifen resistance is downregulation
of phosphatase activities, rather than kinase activation. In collaboration with the
Tannenbaum lab, we analyzed the relationships between deregulated phosphatase
activities and tyrosine phosphorylation events. Tamoxifen resistant cells express
inducible nitric oxide synthase (iNOS) whereas Tamoxifen sensitive cells do not
express iNOS (K. Pant, personal communication). Phosphatases such as PTEN
and BDP-1 are S-nitrosated at cysteine residues in Tamoxifen resistant cells
expressing iNOS. S-nitrosated phosphatases often become inactive due to the
lack of functional, presumsbly catalytic, cysteine residues involved in their
enzymatic reactions.
While 100nM Tamoxifen fails to suppress growth of Tamoxifen resistant
cells, combinatorial treatment of Tamoxifen and NOS inhibitors affect growth of
these cells (K. Pant, personal communication). Use of NOS inhibitors reversed the
S-nitrosation on PTEN and BDP-1 in Tamoxifen resistant cells. As Tamoxifen
treatment perturbs tyrosine phosphorylation events in Tamoxifen resistant cells, we
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analyzed the effects of combinatorial treatment of Tamoxifen and a NOS inhibitor on
tyrosine phosphorylation events. We employed two NOS inhibitors (1400W and
S-methylthiocitrulline (SMTC)) at either 1 mM or 0.3mM.
of 100nM Tamoxifen and 1mM
Combinatorial treatments
1400W or 0.3mM SMTC suppress growth of
MCF7-TAM and MCF7-HER2 cells to a similar extent, while combinatorial treatment
of 1 OOnM Tamoxifen and 1 mM SMTC has a stronger growth suppression effect (K.
Pant, personal communication).
MCF7-TAM cells were treated with Tamoxifen alone,
combination with two different NOS inhibitors.
or Tamoxifen in
MCF7-TAM cell samples were
subjected to anti-pY immunoprecipitation-IMAC-LC-MS/MS
analytical replicates were performed (Figure 19).
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analyses. Two
Cell: MCF7-TAM
Peptide amount: 1mg for each condition, total 4mg
NOS inhibitor treatment and iTRAQ label
Tamoxifen alone
Tamoxifen + 1400W
Tamoxifen + SMTC 1mM
Tamoxifen + SMTC 0.3mM
0 Replicate 1 (34)Replicate 2 (30)
Total pY sites (43)
Figure 19. Summary of mass spec analyses for MCF7-TAM cells with Tamoxifen
and NOS inhibitor treatments.
In total, 43 tyrosine phosphorylation sites were identified and quantified. Twenty-one
phosphorylation sites were identified in both analyses, while 13 and 9
phosphorylation sites were identified in either analytical replicate. The number of
tyrosine phosphorylation sites identified from each replicate is 34 and 30, indicating
that basal tyrosine phosphorylation levels in MCF7-TAM are relatively low as typical
mass spec analyses of cell lines yield higher numbers.
In addition to analyses of MCF7-TAM, tyrosine phosphorylation analyses of
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MCF7-HER2 with combinatorial Tamoxifen and NOS inhibitor treatments were
MCF7-HER2 cell samples were subjected to anti-pY
immunoprecipitation-MAC-LC-MS/MS analyses. Two analytical
performed (Figure 20).
Cell: MCF7-HER2
NOS inhibitor treatment and iTRAQ label
114: Tamoxifen alone
115: Tamoxifen + 1400W
116: Tamoxifen + SMTC 1mM
117: Tamoxifen + SMTC 0.3mM
Replicate 1
Replicate 2
replicates were
(47)
(46)
Total pY sites (72)
Figure 20. Summary of mass spec analyses for MCF7-HER2 cells with Tamoxifen
and NOS inhibitor treatments.
A total of 72 tyrosine phosphorylation sites were identified and quantified.
Twenty-two phosphorylation sites were identified in both analyses. Considering
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performed.
approximately 60% reproducibility of mass spec analyses of identical samples in
information dependent acquisition modes, 22 overlapping phosphorylation sites
(47%) were lower than expected.
in either analytical replicate.
identified from each replicate
25 and 24 phosphorylation sites were identified
The number of tyrosine phosphorylation sites
is 47 and 46, indicating that basal tyrosine
phosphorylation levels of MCF7-HER2 are higher relative to MCF7-TAM.
/1.3.12 P13K p85 pY605 increases with NOS inhibitor treatments
MCF7-TAM and MCF7-HER2.
The quantification of tyrosine phosphorylation analyses for MCF7-TAM and
MCF7-HER2 treated with Tamoxifen and NOS inhibitors is listed in Table 2 and 3.
The quantification were normalized to Tamoxifen treatement alone (iTRAQ114) in
the all four analyses. Among the phosphorylation sites identified, P13K p85 pY605
was detected in one of the two analytical replicates for MCF7-TAM data sets, and
the phosphorylation site was detected in both analytical replicates for MCF7-HER2
data sets, enabling comparisons of the change at P13K p85 pY605 in both
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P13K p85 pY605 was increased in all NOS inhibitor
treatment conditions in MCF7-TAM cells (between 20-104%). Interestingly, P13K
p85 pY605 was also increased in MCF7-HER2 cells under all NOS inhibitor
treatment conditions (between 67-79%). From the previous Scansite analyses,
P13K p85 pY605 is predicted to interact with the SH2 domain on another P13K p85
subunit in order to recruit a P13K catalytic subunit to fully activate the trimeric class I
P13K. Thus P13K pY605 is a potential indicator for P13K activity, with incrasing
phosphorylation predicting increasing activity.
While further experimental validations are required, the possible
consequences in the P13K activity after Tamoxifen treatment compared to the
combinatorial treatment could be described as below (Figure 21).
MCF7-TAM MCF7-HER2
PIP 3
PTEN
0 en
PIP2
P13K
PIP3
Akt
NOS
PTEN
en0o
P13K Akt
HER2
I
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MCF7-TAM and MCF7-HER2.
Figure 21. P13K-Akt pathways in MCF7-TAM and MCF7-HER2 with Tamoxifen
treatment.
HER2 expression strengthens P13K activity in MCF7-HER2 cells. Tamoxifen
treatment potentially increases P13K activity in MCF7-TAM and MCF7-HER2, while
such increase was not previously seen in the parental MCF7 cell line.
treatment induces iNOS expression and NOS
Tamoxifen
production in MCF7-TAM and
MCF7-HER2. Phosphatases including PTEN and BDP-1 are S-nitrosated at
cysteine residues in response to iNOS expression and NOS production, resulting in
decrease in phosphatase activities. Akt pS473 is increased
MCF7-TAM and MCF7-HER2 in response to Tamoxifen treatment as previously
described in the ELISA experiments and western blots (K.
communication).
Pant, personal
These data are consistent with the model show in figure 21.
Unlike Tamoxifen treatment alone, combinatorial treatments with Tamoxifen
and NOS inhibitors may result in the following changes in P13K pathways (Figure
22).
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Figure 22. PI3K-Akt pathways in MCF7-TAM and MCF7-HER2 with Tamoxifen
treatment and NOS inhibitor combinatorial treatments.
NO production decreases due to iNOS inhibition, resulting in potential recovery of
phosphatase activities such as PTEN activity. Normal PTEN activity restores the
balance between PIP2 and PIP3 levels, resulting in restored Akt
MCF7-TAM. In MCF7-HER2, restored PTEN activity may not be able to maintain
the same balance between PIP 2 and PIP3 levels because of potent signals from
HER2 to activate a P13K activity, resulting in minimal decrease in Akt
phosphorylation. Akt activity measured by Akt pS473 decreases in response to
NOS inhibitor treatment in MCF7-TAM, but not in the MCF7-HER2 (K. Pant,
personal communication), indicating that NOS inhibition leads to restored Akt
activity in MCF7-TAM but HER2 overexpression supersedes Akt regulation through
PTEN S-nitrosation.
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In summary, potential consequences of Tamoxifen and NOS inhibitor
treatments on P13K-Akt pathways are shown in Figure 23.
MCF7-TAM MCF7-HER2
z
0I PIP 3 - PIP 2  IP3  PIP2  HER2
CD / / T\
Akt PTEN P13K Akt PTEN P13K
PIP 3  PIP2  PIP3  PIP2  HER2
Akt PTEN P13K Akt PTEN P13K
0OS0NONOSNO
PIP3
T
PTEN
PIP2
P13K Akt
PIP3 -
'T
PTEN
PIP2  HER2
P13K
WAS
Figure 23. Summary of P13K pathways in MCF7-TAM and MCF7-HER2 with
Tamoxifen and NOS inhibitor treatments.
While multiple phosphorylation events observed in the data support the above
model, additional biological replicates would greatly increase confidence in this
model. Additionally, independent approaches to testing this model have been
explored. Measurements of NO concentration inside Tamoxifen resistant cells
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indicated that NO concentration was increased in response to Tamoxifen treatment
(K.Pant, personal communication). In addition to NO measurements, identification
of the S-nitrosated cysteine residues on phosphatases including PTEN and in vitro
phosphatase assays provide evidence for the hypothesis that Tamoxifen treatment
deactivates phosphatase activity via iNOS induction and NO productions.
11.3.13 Rescue of MCF7-HER2 cells from Tamoxifen treatment with growth
factors
While MCF7-HER2 remains sensitive to Tamoxifen treatment and shows
partial resistance to Tamoxifen compared to parental MCF7, it remained unclear
what roles HER2 plays in addition to providing cells with growth signals and
possibly cross-talking to ER pathways. Due to emerging reports of cross-talk
between receptor tyrosine kinases that are not previously known to heterodimerize
(Huang et al., 2007) (Rexer et al., 2009), I tested if receptor tyrosine kinases
expressed in MCF7-HER2 cells show any sign of cross-talk. As MCF7 cells
express high level of Insulin-like growth factor-1 receptor (IGF1-R), we conducted
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experiments testing the effects of IGF1 treatments on parental MCF7 and
MCF7-HER2, hypothesizing that HER2 overexpression may result in phenotypic
differences when exposed to IGF1 treatments. We treated both parental MCF7
and MCF7-HER2 with 100nM or 1uM Tamoxifen, which lead to decreased viable
cell numbers in both cells. In order to test if growth-promoting characteristics of
IGF1 affect a number of viable cells, 1 0Ong/ml (saturating dose) of IGF1 is added to
the cell culture media (Figure 24). As additional conditions for the study, we used
EGF and HRG as a stimulant of HER2 mediated signaling pathways at 100ng/ml
(saturating dose). The aims of these experiments were to test if any of these
growth factor treatments rescue either the parental MCF7 or MCF7-HER2 from
Tamoxifen treatments.
Both 100nM and 1uM Tamoxifen could suppress the growth of parental
MCF7. When EGF, HRG or IGF1 is added to media, parental cells showed a
marginal increase in the number of the viable cell. As parental MCF7 express high
levels of IGF1-R, low levels of EGFR and HER2, the results indicates that
suppression of growth by Tamoxifen is more potent than the growth promoting
effects from the IGF1, EGF or HRG treatments, although partial rescue was
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observed.
In contrast, MCF7-HER2 responded to IGF1, EGF, and HRG and the
number of the viable cells were the same as the control condition even with
Tamoxifen treatment. The rescue effects are present in both 1 OOnM and 1 uM
Tamoxifen treatment, indicating that a saturating dose of each growth factor
treatments is more potent than the growth suppression from Tamoxifen treatments.
We predicted that EGF and HRG treatments would have better rescue outcomes in
MCF7-HER2 than parental MCF7 due to HER2 overexpression. However, we
predicted that IGF1 treatment would have similar effects in MCF7-HER2 and
parental MCF7 as IGF1-R expression are predicted to be similar in both cell types.
Surprisingly, IGF1 treatment showed strong rescue effect in MCF7-HER2 cells but
such rescue effect was not seen in parental MCF7.
We have not measured the expression levels of IGF -R, EGFR, or HER3 in
MCF7-HER2 cells relative to parental MCF7. As overexpression of a receptor
tyrosine kinase is known to potentially affect expression levels of other receptor
tyrosine kinases, the exact mechanisms through which IGF1 mediates rescue of
MCF7-HER2 cells from Tamoxifen treatment remain unclear. It is possible that the
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IGF1-R expression level is higher in MCF7-HER2 which caused potent IGF1-R
signals. IGF1 is known to bind IGF1-R and Insulin receptor (IR) depending on
expression levels of each receptor and doses of IGF1. The saturating dose of
IGF1 used in this study potentially affects both IGF1-R and IR activation. The
activated IGF -R and IR signaling networks might be amplified by, and/or cross-talk
to HER2 signaling network in the MCF7-HER2, leading to phenotypically different
outcomes compared to parental MCF7. Another potentially relevant experiment is
to conduct the same rescue experiments in the presence of insulin. The MCF7 cell
line is known to grow better in the media containing insulin. In order to better
understand the effects of each growth factor on MCF7-HER2, it may be important to
conduct titration experiments. In addition, MS analyses of tyrosine
phosphorylation events in MCF7-HER2 cells with growth factor stimulation may
highlight potential cross-activations of receptor tyrosine kinase and downstream
signaling events. As IGF1-R is an important therapeutic target in multiple
malignancies, better understanding of potential cross-talk mechanisms between
IGF1-R and HER2 are of significant interest.
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Figure 24. Rescue experiments with HRG, EGF1 and IGF1 on parental MCF7 and
MCF7-HER2. Cells are counted at the day 9 for the parental MCF7 cells, and the
day 6 for the MCF7-HER2 cells.
11.3.14 Migration and invasion abilities of Tamoxifen resistant cells
Adhesion molecules controlling cell-cell attachments and cellular
locomotion are highly regulated by post-translational modification such as
phosphorylation. Potential consequences of hyperphosphorylation on adhesion
molecules in Tamoxifen resistant cell lines include increased migratory and invasive
abilities. In order to test if Tamoxifen treatment makes Tamoxifen resistant cells
more migratory and invasive, we have conducted transmembrane migration assays
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ParentalMCF
MCF7-HER2
and matrigel invasion assays with Boyden chambers. Both migration and invasion
assays were conducted 24, 48, and 72 hours after seeding cells in Boyden
chambers. There were no differences between time points, indicating that 24 hours
is long enough for any mobile cells to pass through the holes in the membrane (data
not shown). The lower chambers of each well are filled with the full growth media
which contains chemoattractants present in FBS. Experimental design, a
representative image and results from migration assays are shown in Figure 25.
Orange = 100ul Serum free DMEM with cells (1 x1 05
cells/cm 2) (For invasion assay, Matrigel is 100ul of
1:30 diluted in serum free DMEM)
Pink = 500ul 10% FBS in DMEM
Well 1 Well 2 Well 3 Ave.
MCF7-Parental, day 9, control 12 20 9 13.6
MCF7-HER2, day 6, control 22 28 31 27.0
MCF7-TAM, day 9, control 26 14 18 19.3
MCF7-Parental, day 15, Tamoxifen 21 20 13 18.0
MCF7-HER2, day 15, Tamoxifen 17 40 20 25.6
MCF7-TAM, day 15, Tamoxifen 21 11 16 19.3
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Figure 25. Migration assay design and results. Experimental design of Boyden
chamber, image of migrated cells at the bottom of membrane. The numbers are
sum of measurements from two non-overlapping areas in each well.
To our surprise, the number of cells on the bottom side of the membrane was
considerably low compared to the numbers expected similar membrane migration
experiments with other breast cancer cell lines. Because the number of migrated
cells was low, it was difficult to assess if Tamoxifen treatment made Tamoxifen
resistant cells more migratory than vehicle treatment did. As the number of the
migrated cells was low, the results from the invasion assay were even lower as cells
not only have to pass membrane but also a matrigel layer (data not shown).
In order to add positive control conditions and test the validity of migration
assay conditions, T47D and Met2A cell lines were tested for their migration ability in
the same migration experimental settings (Figure 26). Both Met2A and T47D
migrated through membrane, indicating that the protocol is valid for these two cell
lines to show migration ability.
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Figure 26. Migration assay with Met2A and T47D. Presence of 10% serum in
bottom chamber makes both cell lines migrate. Note the higher number of
migrated cells compared to MCF7 cells. Error bars are calculated from two wells in
analytical replicates. Met2A with serum has an error bar, but too small to be visible
in this figure.
MCF7 cells express high levels of E-cadherin, making them tightly anchored
to each other. In order to re-test the migratory and invasive ability of Tamoxifen
resistant cells in relatively favorable conditions for MCF7 cells to migrate, we used
E-cadherin neutralizing antibodies to dissociate tightly anchored MCF7 cells during
seeding of the top layer of the membrane during the migration assay. (Figure 27).
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With Ab Without Ab
Figure 27. Migration assay with E-cadherin antibody treatment.
According to manufactures protocol for E-cadherin, 12ug/ml antibody would be
sufficient for inhibitory experiments in cell culture. However, such treatment did not
result in increase in migration of MCF7 cells (data not shown). We repeated
experiments with 1 00ug/ml antibody, and obtained results above. E-cadherin
treated MCF7 cells are more migratory than MCF7 cells without E-cadherin
antibody treatments. Contrary to our expectation, Tamoxifen treated MCF7 cells
were less migratory than control treated cells.
At 1 00ug/ml E-cadherin antibody treatments, there was a marginal increase
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in the number of invasive MCF7 cells, with MCF7-HER2 cells being more invasive
than parental MCF7 and MCF7-TAM (Figure 28).
With Ab Without Ab
Figure 28. Invasion assay with E-cadherin antibody.
The effects of E-cadherin antibody treatment on the number of invasive cells were
not as obvious as the effects seen in migration assays. Tamoxifen treatment did
not increase the invasive ability of MCF7 cell lines. A major challenge in both
migration and invasion assay with MCF7 cells is that the tightly-bound nature of
MCF7 cells makes cells difficult to move despite treatment with E-cadherin
antibody, which neutralizes E-cadherin function and loosens cell-cell contacts
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mediated by E-cadherin.
148
11.4 Discussions
Tamoxifen resistance is an unmet medical need affecting a large number of
patients with ER-positive breast cancer that have taken this therapeutic SERM. To
address this problem we have applied an unbiased, mass spectrometry-based,
quantitative proteomic analyses of protein phosphorylation to cell line models of
Tamoxifen resistance. Our goal in this study was two-fold: first, to identify changes
in the tyrosine phosphorylation-mediated signaling network caused by 4-OHT
exposure; and second, to determine if this information would provide a potential
therapeutic strategy to revert Tamoxifen resistance in different resistance models.
Our analyses revealed that Tamoxifen resistant cell lines have the ability to maintain
a high level of proliferation and activate anti-apoptotic signals in response to 4-OHT
exposure, while the Tamoxifen sensitive cell line does not have the same capacity.
In addition to the pro-survival (P13K-Akt) and pro-proliferation (Erk) pathways, we
also observed multiple hyperphosphorylated sites on adhesion and cytoskeletal
proteins in MCF7-HER2, and to a lesser extent, MCF7-TAM cells in response to
4-OHT treatment. These molecules are likely controlled directly or indirectly by
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increased activities of Src and FAK, but other pathway components cannot be ruled
out. In fact, motif analysis
phosphorylation
of the amino acid sequences surrounding
sites that increased phosphorylation in response to 4-OHT
exposure in the MCF7-HER2 cells yielded a statistically significant enrichment of
the AbI kinase motif. AbI is activated by Src and has been shown to promote
invasion of aggressive breast cancer cells (Srinivasan and Plattner, 2006). Since
dasatinib inhibits Src- and Abl-family kinases, with this compound it is not possible
to distinguish whether Src or Abi is the principal driver modulating Tamoxifen
resistance in the MCF7-HER2 and MCF7-TAM cell lines. However, given that this
compound is currently used in the clinic as a second-line therapeutic for chronic
myeloid leukemia, dasatinib may represent a clinically relevant option to revert
Tamoxifen resistance regardless of the driving kinase.
It is also worth noting that since phosphorylation of catenin 61, catenin 62
and paxillin has been linked to detachment of cell-cell adhesions,
phosphorylation changes induced by 4-OHT may lead to increased migration and/or
invasive potential (Hiscox et al., 2006). Moreover, since HER2 overexpression
activates the cellular migration signaling network (Wolf-Yadlin et al., 2006), our
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these
quantitative phosphorylation data indicates that Tamoxifen treatment of HER2
overexpressing cells may further increase the migratory and invasive potential of
these cells, leading to increased aggressiveness.
The unbiased approach we have demonstrated here represents a valuable
method to identify key signaling nodes at multiple layers in the complex network
regulating therapeutic resistance. While perturbation of these nodes may not
revert therapeutic resistance in every instance, here we have provided several
examples in which inhibition of key nodes in the network has diminished Tamoxifen
resistance to varying degrees, dependent on cell context. In the future, it might be
possible to use selected phosphorylation sites (e.g. HER2 pY1248, catenin 62
pY424 and pY499, or paxillin pY118) as markers to select the best therapeutic
option (e.g. gefitinib, dasatinib, others) to revert or prevent Tamoxifen resistance,
representing a potential application of personalized medicine for breast cancer
patients.
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111.1 SUMMARY
A subclass of non-small cell lung cancers (NSCLCs) expresses EML4-ALK
chimeric oncogene. The EML4-ALK protein is a constitutively active tyrosine
kinase with a transforming activity in NIH-3T3 fibroblast cells. Cell culture studies
and transgenic mouse studies showed that EML4-ALK is a potential therapeutic
target among a subclass of NSCLC patients. While the characteristics of
EML4-ALK as a transforming gene and a constitutively active tyrosine kinase have
been established, the signaling pathways activated by EML4-ALK remain unclear.
In order to better understand EML4-ALK signaling networks, we used quantitative
phosphoproteomic analyses by mass spectrometry to identify the tyrosine
phosphorylation sites responsive to EML4-ALK expression. Results from the
mass spec analyses revealed a number of highly phosphorylated proteins and their
phosphorylation sites in 3T3 cells that are stably transfected with an EML4-ALK
gene. Validations of EML4-ALK-specific phosphorylation sites by orthogonal
methodologies showed that endogenous EML1 and EML4 are potential direct
EML4-ALK substrates. Moreover, EML1 and EML4 may function as scaffolds in
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order to recruit other EML4-ALK substrates to propagate the signals.
obtained from this collaborative project shine light on novel EML4-ALK signaling
pathways which are required to better understand its carcinogenic roles in NSCLCs.
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Results
111.2 INTRODUCTION
Lung cancer is one of the most difficult malignancies to cure among all
cancers. Lung cancer is the leading cause of cancer related deaths. The number
of new lung cancer cases is over 174,000 and the number of lung cancer related
deaths is over 162,000 in the USA in 2005 (Jemal et al., 2006). Unfortunately, use
of conventional chemotherapeutics rarely leads to cure mainly because of limited
efficacy and because the majority of lung cancer patients are diagnosed at later
stages of the disease (Schiller et al., 2002). Non-small cell lung cancers
(NSCLCs) account for an approximately 80% of all lung cancer cases. Within
NSCLC patients, a small subset of the patients carries EGFR activating mutations
and such patients respond to the EGFR kinase inhibitor Iressa (Lynch et al., 2004),
suggesting the mutated EGFR's critical role as a driver oncogene in this subset of
patients (Paez et al., 2004). Improvements in the clinical outcomes of NSCLC
patient populations without activating EGFR mutations are highly desired. Such
improvements could be achieved by identifying promising therapeutic targets which
are critical for tumor progression, as in the case of NSCLCs with mutated EGFR.
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In order to identify novel driver oncogenes in NSCLCs, Soda et.al performed gene
screenings with a retrovirus-mediated cDNA expression library created from a
62-year old NSCLC patient's specimen (Soda et al., 2007). As a result of infecting
NIH-3T3 fibroblasts with the cDNA library and performing transformation assays,
many transformed foci are formed, leading to the isolation and identification of
cDNAs which caused foci formations. One of the isolated cDNAs was identified to
contain an amino-terminal portion of human echinoderm microtubule-associated
protein-like protein 4 (EML4) fused with a carboxyl-terminal portion of human
anaplastic lymphoma kinase (ALK) including its tyrosine kinase domain. The
biochemical assays analyzing this EML4-ALK fusion gene expressed in cell culture
showed that the gene product is a transforming, constitutively active tyrosine kinase.
EML4-ALK
dimerization.
exists as a homodimer because the EML4 domain promotes
EML4-ALK interacts with microtubules in the cytoplasm, while
wild-type ALK is a cell membrane embedded receptor tyrosine kinase. In addition
to the original EML4-ALK, analysis of additional NSCLC specimens by RT-PCR with
primers detecting EML4-ALK fusions identified additional EML4-ALK variants with
distinctive gene fusion-points. The different variants of EML4-ALK all have the
163
ALK tyrosine kinase domain and gene fusion-points at similar locations as the
original EML4-ALK gene,
tyrosine kinases.
the observations,
indicating that the variants are constitutively active
Although analyses of more specimens are required to generalize
EML4-ALK* NSCLC specimens are absent for both EGFR
mutations and KRAS mutations, suggesting the EML4-ALK+ NSCLCs as a novel
subclass within NSCLCs. Inhibition of EML4-ALK with ALK kinase
(WHI-P154) in the classic IL-3 dependent BaF3 transformation assays showed
EML4-ALK's potential as a novel therapeutic target.
All of the characterizations described above were conducted in the NIH-3T3,
HEK293, and BaF3 cell lines transfected with EML4-ALK. While such studies in
cell lines are valuable, EML4-ALK's carcinogenic roles in the development and
progression of NSCLCs remains unclear. In order to study EML4-ALK's
carcinogenic role in a more physiological setting, tissue-specific transgenic mice
that express EML4-ALK in lung epithelial cells were created. EML4-ALK knock-in
mice developed a number of adenocarcinomas in both lungs of all transgenic mice,
and mice died within six months after their birth (Soda et al., 2008). Importantly,
oral administration of ALK kinase inhibitor 2,4-Pyrimidine-diamines derivative,
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inhibitor
reduced tumor burden in all EML4-ALK transgenic mice, indicating that EML4-ALK
induces carcinogenesis in the lungs of transgenic mice and an ALK inhibitor is
effective in reducing the EML4-ALK induced carcinogenesis in the transgenic
mouse model.
Although much work has been done to show the importance of EML4-ALK
in lung carcinogenesis and its potential as a therapeutic target, the molecular
signaling mechanisms by which EML4-ALK transforms normal cells and drives
carcinogenesis remain unclear. In order to reveal potential carcinogenic
mechanisms and activated signaling networks by EML4-ALK, we analyzed tyrosine
phosphorylation events with a quantitative phosphoproteomic approach by mass
spectrometry. Results from these analyses identified the tyrosine phosphorylation
sites that are particularly responsive to EML4-ALK in 3T3 cells. Selected
phosphorylation sites are validated by orthogonal methods in which EML4-ALK and
each plasmid containing potential EML4-ALK target are co-expressed. Importantly,
analyses of kinase-target interactions suggested the potential roles of endogenous
EML1 and EML4 proteins as components of multi-phosphoprotein complexes.
Results indicated that the multi-protein complex include a large number of
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The overall results reveal the important 'tip of iceberg' of
potential pathways through which EML4-ALK initiates transformation
fibroblasts, some of which are potentially conserved in NSCLCs.
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in 3T3
EML-4-ALK substrates.
111.3 MATERIALS and METHODS
111.3.1 Cell lines and reagents
The NIH-3T3 mouse fibroblast cells were stably transfected with retrovirus
carrying 1) a vector with EML4-ALK L583M Kinase Dead Mutant (termed the KM
which function as a negative control in this study), 2) a vector with wild type ALK, 3)
a vector with EML4-ALK variant 1, or 4) a vector with EML4-ALK variant 3b in Mano
lab in Jichi Medical University, Japan.
selected by the antibiotic selection. Up
Cells that were stably transfected were
on arrival of frozen cell stocks to White Lab
at MIT, cells are thawed and cultured in DMEM supplemented with 10% FBS until
each plate reaches confluence. Cells are routinely subcultured at 1:10 when each
plate reached confluence. Five frozen cell vial stocks of are prepared from one
confluent 10cm cell culture plate and stored in a liquid nitrogen tank for future use.
Fresh frozen stocks of cells are thawed at the beginning of each experiment in order
to maintain consistencies across biological replicates. Cells are subcultured two
rounds before experimental samples are collected. Cell lysate samples for
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western blot analyses are collected from 10cm plates in RIPA buffer supplemented
with PhoStop (Roche Applied Biosciences).
phosphoproteomic analyses
Cell lysate samples for the
are collected from 15cm plates in 8M
supplemented with 10mM sodium orthovanadate. Before collecting cell lysate
samples, each plate were serum starved overnight in DMEM without FBS.
Surprisingly, 3T3 cells expressing EML4-ALK variant 1 and variant 3b detached
from plates a few minutes after serum starvation.
type ALK did not detach from plates after serum starvation.
Cells expressing the KM or wild
In order to avoid cell
detachments from plates, serum starvation step was not conducted in the real
sample preparations. Instead of serum starvation, cells are gently rinsed with 37
degrees Celsius PBS in order to remove residual serum and subsequently lysed
with appropriate lysis buffers. All the cell culture reagents are purchased from
Invitrogen.
111.3.2 Peptide sample preparation.
For mass spectrometry analyses, cells were lysed in 8M urea buffer with
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urea
Cell lysates were reduced with 10mM DTT and
alkylated with 55mM iodoacetamide to block free thiols on cysteine side chains
according to Zhang et. al (Zhang et al., 2005). The chemically modified cell lysate
samples were subjected to tryptic digestion at a 1:100 ratio overnight and resulting
tryptic peptides were desalted on a C18 reverse phase cartridge (Millipore).
Peptides were eluted with 10mL of 25% acetonitrile/0.1% acetic acid, and 500pg
peptide aliquots were lyopholized and stored at -80 degrees Celsius. Two
biological replicate samples were prepared from two independent batches of cell
cultures.
111.3.3 iTRAQ labeling of peptides and Peptide Immunoprecipitation
Peptide samples from 3T3 cell lines with four different vectors were
chemically labeled with iTRAQ reagent according to Zhang et. al (Zhang et al.,
2005). Four-plex iTRAQ reagents were used as follows: iTRAQ 114 for peptides
from 3T3 cells with EML4-ALK Kinase Mutant (KM), iTRAQ 115 for peptides from
3T3 cells with wild-type ALK, iTRAQ 116 for peptides from 3T3 cells with EML4-ALK
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10mM sodium orthovanadate.
variant 1, and iTRAQ1 17 for peptides from 3T3 cells with EML4-ALK variant 3b
(Figure 1). After iTRAQ labeling, peptides were combined and subjected to
anti-phosphotyrosine peptide immunoprecipitation as described (Zhang et al., 2005)
with the following modifications: iTRAQ labeled peptides were incubated with 12pg
of antiphosphotyrosine antibody (P-Tyr-100, (Cell Signaling Technology)) and 12pg
of antiphosphorylation antibody 4G10 (Millipore) in 200ug of immunoprecipitation
buffer for 8 hours at 4C, followed by incubation with 20ug of protein G Plus-agarose
beads (Calbiochem) overnight.
3T3 with Kinase Mutant
3T3 with wild type ALK
3T3 with EML4-ALK v1
3T3 with EML4-ALK v3b
114
Anti-pY IP - IMAC
116
117
ITI1Z
-- + LC-MS
hr)
Figure 1. iTRAQ labeling of tryptic peptides from 3T3 cells with Kinase Mutant
EML4-ALK L583M variant 1, wild type ALK, EML4-ALK variant 1, and EML4-ALK
variant 3b
111.3.4 Immobilized metal affinity chromatography (IMAC) and Mass
Spectrometry
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anti-phosphotyrosine
phosphopeptides were further enriched by immobilized metal affinity
chromatography (IMAC) which removes non-specifically bound peptides from the
immunoprecipitation (Moser and White, 2006). Peptides retained on an IMAC
column were eluted with 250mM sodium phosphate at pH8.0 and analyzed by
electrospray ionization liquid chromatography tandem MS on QSTAR XL Pro Mass
Spectrometer (Applied Biosystems) (Zhang et al., 2005). MS/MS spectra were
extracted, searched with Mascot (Matrix Science), and quantified with ProQuant
(Applied Biosystems). Phosphorylation sites and peptide sequence assignments
were validated by manual confirmation by assigning spectra of raw MS/MS data.
Area under the peaks of iTRAQ reporter ions from phosphopeptides were
normalized with values from the area under the peaks of iTRAQ reporter ion from
non-phosphorylated peptides which is obtained from running combined iTRAQ
peptides from supernatant of peptide immunoprecipitation on mass spectrometer.
Total peptide quantification for each condition was measured by averaging peptide
quantities from abundant house keeping genes that are expressed relatively
constant levels, including but not limited to actin, tubulin, and HSP90.
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immunoprecipitation,Following peptide
111.3.5 Cell Titer Gro and WST-1 Assays
The KM, wild-type ALK, EML4-ALK v1, EML4-ALK v3b expressing 3T3 cell
lines are thawed and passaged twice. Appropriate numbers of cells (1000, 3000,
10000) are seed onto 96 black well plates for cell titer gro assay, and clear 96 well
plates for WST-1 assay. Seeded cells are undisrupted overnight and cell titer gro
assay (Promega) and WST-1 (Roch Applied Bioscience) assays are performed
according to manufactures protocols.
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111.4 RESULTS
Two analytical replicates from two biological replicates (a total of four MS
runs) are analyzed by quantitative mass spectrometry. Runs #1 and #2 are from
the first biological replicate, and runs #3 and #4 are from the second biological
replicate. Runs #1 and #4 had higher intensities of phosphopeptides and more
phosphorylation sites detected than runs #2 and #3, respectively. For these
reasons, run #1 and #4 were processed for quantification and manual spectra
validation in order to obtain standard deviations and confirm identification of
phosphorylation sites. From the compilation of run #1 and #4, 84 total tyrosine
phosphorylation sites were identified and quantified. Out of 84 tyrosine
phosphorylation sites, 55 are detected in both analyses (65%), while 29 sites are
detected once in either run #1 or #4. A list of the 84 tyrosine phosphorylation sites,
relative quantification across four conditions, standard deviations for 55 sites, and
fold changes relative to the kinase mutant negative control are listed in table 2.
111.4.1 Wild type ALK and EML4-ALK activities measured by ALK pY1 096
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The phosphorylation at tyrosine 1096 of ALK (ALK pY1 096) is in close
proximity to its tyrosine kinase domain. ALK pY1096 is correlated to ALK kinase
activities according to Phosphosite (www.phosphosite.org).
peaks from an ALK pY1096 peptide are shown in Figure 2.
iTRAQ reporter ion
In the kinase dead
mutant (the KM), ALK pY1096 was nearly absent (iTRAQ 114) indicating that the
ALK activity is nearly absent in the KM sample. Relative to the KM, ALK pY1096
was 19.9-, 18.6-, and 32.5-fold higher in wild type ALK (iTRAQ 115), EML4-ALK v1
(iTRAQ 116), and EML4-ALK v3b (iTRAQ 117) respectively, indicating that ALK
activities are higher in these three samples relative to the KM sample. In the wild
type ALK sample, it is possible that FBS in the growth media contained ALK ligands
for ligand-mediated activations. 3T3 cells transfected with wild type ALK grow
preferably in close cell-cell contacts compared to the KM or EML4-ALK transfected
3T3 cells (data not shown). This specific phenotype indicates that 3T3 cells with
wild type ALK have growth advantages when cells are in contact to each other.
This is potentially because overexpressed wild type ALKs are activated by cell-cell
contacts, either by cell surface ligands displayed on neighboring cells and/or other
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proteins which is on outer surface of cell membrane.
v3b expressing 3T3 cell samples, ALK pY1096 are 18.6- and 32.5-fold higher than
the KM. As 3T3 cells do not express wild type ALK, the ALK pY1 096 is most likely
from EML4-ALK transgenes. Before collecting cell lysate samples, each plate
were serum starved overnight in DMEM without FBS. Surprisingly, 3T3 cells
expressing EML4-ALK variant 1 and variant 3b detached from plates a few minutes
after serum starvation.
from plates after serum starvation.
Cells expressing the KM or wild type ALK did not detach
In order to avoid cell detachments from plates,
serum starvation step was not conducted in the real sample preparations. Instead
of serum starvation, cells are gently rinsed with 37 degrees Celsius PBS in order to
remove residual serum and subsequently lysed with appropriate lysis buffers.
Because serum starvation was not possible during sample preparation, it is
probable that the FBS may activate signaling networks which may affect ALK
pY1096, in addition to the previously proposed EML4-mediated oligomerization
leading to EML4-ALK activation. Based on the strong increases on ALK pY1 096 in
wild type ALK, EML4-ALK v1, and v3 transfected 3T3 cells, we analyzed 83 other
tyrosine phosphorylation sites in order to propose potential mechanisms of
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In the EML-4-ALK v1 and
EML4-ALK oncogenic signaling events.
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Figure 2. iTRAQ reporter ion peaks from an ALK pY1 096 peptide. Representative
iTRAQ reporter ion peaks from two biological replicate are shown.
111.4.2 Endogenous EML4 and EMLI are phosphorylated in EML4-ALK
dependent manners
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(inase Mutant
Several phosphorylation sites are found to be specifically responsive to
EML4-ALK activities. Endogenous EML4 and EML1 are highly phosphorylated in
EML4-ALK v1 and EML4-ALK v3b expressing 3T3 cells, but not in the KM or wild
type ALK expressing 3T3 cells. Since 3T3 cells are mouse fibroblasts,
distinguished the slight amino acid differences in EML4 peptide sequences between
human EML4-ALK transgenes and the endogenous EML4 protein, showing that the
EML4 pY 226 detected is on the endogenous EML4 and not at the N-terminal part
of EML4-ALK transgene. Endogenous EML4 pY226 is 11.9- and 18.0-fold higher
in EML4-ALK v1 and EML4-ALK v3b expressing 3T3 cells than
Endogenous EML1 is 35.2- and 51.2-fold higher in EML4-ALK v1 and EML4-ALK
v3b expressing cells compared to the KM. In contrast, endogenous EML4 pY226
and EML1 pY186 are only 1.5- and 1.1-fold higher in ALK expressing 3T3 cells
compared to the KM, showing that these two phosphorylation sites are increased by
EML4-ALK but not by wild type AKL. Additionally, we detected endogenous EML1
pY396 which did not significantly change across four conditions, indicating that this
phosphorylation site is not regulated by either ALK or EML4-ALK
experimental system. IRS-2 has previously been proposed as a potential
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we
the KM.
in this
downstream component of EML4-ALK in EML4-ALK* positive lung tumor samples
(Rikova et al., 2007). We found that IRS-2 pY776 is 2.1- and 7.5-fold higher in
EML4-ALK v1 and EML4-ALK v3b samples respectively, whereas it remains
unchanged in wild type ALK transfected 3T3 cells.
111.4.3. ALK and EML4-ALK dependent phosphorylation sites
In order to sort the 84 sites based on quantification patterns across four
conditions, hierachical clustering was conducted by Spotf ire (Figure 3).
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Figure 3. Hierachical clustering of 84 tyrosine phosphorylation sites. Relative
quantification is normalized to the most abundant iTRAQ peak for each
phosphorylation site. Scale is in percent. A cluster that responds to EML4-ALK, and
three clusters that respond to both wild type ALK and EML4-ALK are shown.
A number of phosphorylation sites that increase in both wild type ALK and
EML4-ALK dependent manners are clustered. These phosphorylation sites can
be divided into three categories: A) the most responsive to EML4-ALK v3b, B) the
most responsive to EML4-ALK v1, and C) the most responsive to wild type ALK.
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As summarized in figure 3, cluster A includes actin pY220, SHC pY423, SDN pY1 09,
and ALK pY1096. Cluster B includes RAN pY155, PGK pY196, HSP90B pY483,
PKM2 pY105, RAN pY147, PKM2 pY390, OKM2 pY175. Cluster C includes
LDH-A pY238, PSAT pY346, WDR pY237, NCK pY1 10, PSMA pY56, ANXA pY315,
LOC328092 pY162, GMD pY323, ITSN2 pY921, ENO pY43, and FER pY715. In
cluster A, ALK pY1096 is an indicative of ALK activity. 3T3 cells expressing
EML4-ALK v3b have the highest ALK pY1 096 which could be due to differences in
transgene expression levels and/or due to higher ALK activity of EML4-ALK v3b
relative to wild type ALK and EML4 ALK v1. SHC pY423 regulates association of
adaptor molecules to induce their interactions with Grb2 (Faisal et al., 2004;
Sasaoka et al., 2001; Zhang et al., 2002). SND1, which is alternatively known as a
p105 co-activator, is a co-activator of STAT6, bridging STAT6 with RNA Polymerase
I in order to initiate transcription at STAT6 regulated genes. In category B, as
EML4-ALK localize in microtubules, highly phosphorylated RAN pY155 and pY147
indicate regulations of microtubule networks by RAN, independently of its roles in
the transport of macromolecules between nucleus and cytosol. HSP90B pY483 is
highly phosphorylated in both EML4-ALK and ALK dependent manners (4.9-, 14.0-,
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and 8.4-fold in wild type ALK, EML4-ALK v1 and EML4-ALK v3b expressing 3T3
cells compared to the KM). HSP90B is one of the HSP90 isoforms and is an
abundant chaperon protein. PKM2 pY105, pY390, pY175 are highly
phosphorylated in both ALK and EML4-ALK dependent manners. PKM2 pY390 is
particularly highly phosphorylated (13.2-, 22.3-, and 12.4-fold higher in wild type
ALK, EML4-ALK v1 and EML4-ALK v3b expressing 3T3 cells compared to the KM).
PKM2 has recently been shown to be a phosphotyrosine binding protein, even
though it lacks known phosphotyrosine binding SH2 or PTB domains (Christofk et
al., 2008). In category C, a number of vital enzymes in metabolic pathways,
including LDH-A, PSAT, and ENO are highly phosphorylated. LDH-A catalyzes the
reaction between pyruvate and lactate in an NADH dependent manner. ENO
converts 2-phosphoglycerate to phosphoenolpyruvate during glycolysis. PSAT
converts 2-phosphohydroxypruvate into serine during amino acid biosynthesis.
Overall, many enzymes are highly phosphorylated in both wild type ALK and
EML4-ALK dependent manners. As metabolic enzymes are known to be tightly
regulated by post-translational modification, it is possible that signals from ALK and
EML4-ALK modulate activities of enzymes leading to abnormal metabolic pathway
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levels.
111.4.4 ALK dependend phosphorylation sites
Because ALK is a receptor tyrosine kinase signaling from the cell
membrane, we predicted that localization of the EML4-ALK in microtubules results
in at least partial loss of normal ALK signaling pathways. As seen in Figure 4, ALK
high cluster has three phosphorylation sites that are exclusively high in wild type
ALK transfected 3T3 samples.
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Figure 4. Cluster of ALK specific phosphorylation site and one phosphorylation site
that is highly ALK responsive and weakly EML4-ALK responsive is shown.
These sites are HIP pY105, PTTGF11P pY171, and AP2BI pY276. Intriguingly,
common characteristics of these three ALK dependent phosphorylation sites are
that these proteins are membrane associated (Stowers and Isacoff, 2007).
PTTFG11P is a type la integral membrane protein and contains the tetrapeptide
YXRF, a motif observed in proteins internalized by coated pit-mediated endocytosis.
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AP2B1 is a part of the AP2 coat assembly protein complex that link clathrin to many
cell surface receptors. Another ALK dependent phosphorylation site is DBI pY77.
DBI is a protein known to be involved in membrane phospholipid turnovers. Lack
of these four phosphorylation sites in EML4-ALK transfected 3T3 cells indicates that
EML4-ALK localization in proximity to microtubules results in a loss of interactions
between EML4-ALK to the proteins localized cell membrane. It also indicates that
EML4-ALK is not only a constitutively active tyrosine kinase, but also is a distinctive
kinase from wild type ALK in having different downstream pathway components.
111.4.5 Phosphorylation sites that are lost in ALK and EML4-ALK expressing
3T3 cells
There are three proteins which are hypophosphorylated in response to wild
type ALK or EML4-ALK expression in 3T3 cells. These three sites are Eph
A3/A4/A5 pY779, Tensin pY1480, and Caveolin-1 pY14 (Figure 5).
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Figure 5. A cluster of phosphorylation sites that are hypophosphorylated in wild
type ALK and EML4-ALK expressing 3T3 cells.
Caveolin-1 mediates integrin-regulated membrane domain internalization, which is
a mechanism used to shut down growth factor receptor signaling. Decrease in
Caveolin-1 pY14 leads to constitutive activation of growth regulatory pathways, and
often results in anchorage independence (del Pozo et al., 2005). Decreased
Caveolin-1 phosphorylation in both wild type ALK and EML4-ALK expressing 3T3
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cells indicates that growth regulatory pathways are deregulated, leading to fast
growth and anchorage independence. There is no previous literature for Tensin 1
pY1480, and biological functions of the phosphorylation site remain unknown.
111.4.6 Interactions between endogenous EML4 and EML1 with EML4-ALK
After completion of phosphoproteomic analyses, validations of endogenous
EML4 and EML1 phosphorylation sites as EML4-ALK substrates were performed in
the Mano lab at Jichi Medical University. To confirm interactions between the
kinase and its substrates, MYC-tagged EML4-ALK was transfected to 3T3 cells
along with FLAG-tagged human EML1 or human EML4 and anti-MYC
immunoprecipitations followed by anti-FLAG blots are performed (Figure 6).
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Figure 6. Interactions between EML1 or EML4 and EML4-ALK.
Based on this result, human EML1 and human EML4 interact with EML4-ALK. At
this point, it was uncertain if EML1 and EML4 phosphorylation sites are required for
the interaction between EML1 or EML4 and EML4-ALK. In order to test the
function of the EML1 and EML4 phosphorylation site, the tyrosine phosphorylation
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sites on both proteins were mutated to phenylalanine (YF),
experiments were repeated (Figure 7). YF mutant EML1 and EML4 could maintain
interaction with EML4-ALK, although to lesser extents. The weaker interactions
between YF mutant EML1 or YF mutant EML4 and EML4-ALK indicate that a loss of
tyrosine phosphorylation site might be the cause of weaker interactions, although
further experiments with loading controls are necessary to make a conclusion
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Although EML4 proteins are known to homodimerize, it remained unclear if
EML4 can heterodimerize with other EML isoforms such as EML1. In order to test
if EML1 and EML4 interact each other and if the interaction is EML4-ALK dependent,
FLAG-tagged EML4 and HA-tagged EML1 were expressed in 3T3 cells with or
without EML4-ALK, and immunoprecipitations followed by immuno blots were
performed (Figure 8).
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Figure 8. Interactions between EML1 and EML4 occurs in the absence of
EML4-ALK.
The anti-FLAG immunoprecipitation and anti-HA blot, and anti-HA
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immunoprecipitation and anti-FLAG blot confirm interaction of EML1 and EML4.
The interaction was present in the absence of EML4-ALK, while the interaction
seemed to increase in the presence of EML4-ALK, although the loading controls for
this experiment need to be shown. It remains to be seen if the interactions
between EML1 and EML4 will be weaker when EML4-ALK dependent
phosphorylation sites are mutated to phenylalanine.
111.4.7 EML1 and EML4 interact with tyrosine phosphorylated proteins in
EML4-ALK dependent manner.
Although EML1 and EML4 interact with EML4-ALK, the functional
consequences of such interactions remained unclear. In addition, it is possible
that there are additional EML4-ALK substrates that are part of EML4-ALK/EML1
and EML4-ALK/EML4 complexes. In order to analyze EML4-ALK/EML1 and
EML4-ALK/EML4 complexes, FLAG-tagged EML4, EML1, YF mutated EML4 or YF
mutated EML1 were expressed in 3T3 cells in the presence or absence of
MYC-tagged EML4-ALK. Samples are subjected to anti-FLAG
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immunoprecipitation followed by anti-pY blot (Figure 9).
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Figure 9. EML1 and EML4 interact with tyrosine phosphorylated proteins in the
presence of EML4-ALK.
Wild type EML1 and EML4 interact with many tyrosine phosphorylated proteins in
the presence of, but not in the absence of, EML4-ALK. YF mutant EML and YF
mutated EML4 can interact with tyrosine phosphorylated proteins in the presence of
EML4-ALK. These results suggest that 1) tyrosine phosphorylation of EML1 and
EML4 associated proteins occur EML4-ALK dependent manners, and 2) mutant
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EML1 and EML4 maintains partial functions which could be due to the presence of
unidentified EML4-ALK substrate tyrosines on EML1 and EML4.
111.4.8 Analysis of phosphorylation sites on EML1 and EML4
In order to identify additional phosphorylation sites on EML1 and EML4 that
are responsive to EML4-ALK expression, 3T3 cells are co-transfected with EML1 or
EML4 with EML4-ALK. EML1 or EML4 are affinity purified, and run on SDS-PAGE
in order to isolate the EML1 or EML4 containing bands for mass spec analyses
(Figure 10).
193
00%
00
ioo
Z Z
I I
LL
iwo
ZT
O
z
0I
0
U-
zZ0
0
a-
I
U-
z
0
0Q_
EML4-ALK
EML4
EML1
-J
w
L
W
z
0
00.
e- EML4
e- EML1
4-IgG
I I
p-Tyr blot
L I
CBB staining
Figure 10. EML1 and EML4 are immunoprecipitated and blotted with 4G10
phosphotyrosine antibody (left) or stained with the commersie blue (right). The
commercie blue stained bands containing EML1 and EML4 are isolated and
shipped on dry ice to MIT.
Gel bands containing EML1 or EML4 were isolated and in-gel digested in order to
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Three peptide aliquots are prepared from a
single gel band, and two analytical replicate analyses were performed on EML1 and
EML4 gel bands
IMAC-LC-MS/MS,
(total four analyses). We quality-controlled each step of
and analyzed both IMAC-retained
peptides in each analysis. Although a number
and IMAC-flowthrough
of EML1 and EML4
non-phosphorylated peptides are identified in IMAC flow-through, phosphorylated
peptides were not identified in IMAC-retained peptides.
111.4.9 Analysis of energy production and metabolic activity in EML4-ALK
expressing 3T3 cells.
We have hypothesized that EML4-ALK expressing cells maintain a high level of
energy productions and metabolisms. To test this hypothesis, the KM, EML4-ALK
v1, and EML4-ALK v3b expressing 3T3 cells were seeded onto 96 well plates to
conduct a cell titer grow assay and a WST-1 assay (Figure 11).
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perform IMAC-LC-MS/MS analyses.
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Figure 11. Measurement of metabolic activities of 3T3 cells with EML4-ALK Kinase
Mutant, EML4-ALK variant 1, and EML4-ALK variant 3b.
The cell titer gro assay measures total levels of ATP in cells, and WST-1 measures
indirectly a level of NADPH dependent enzymatic activities. Contrary to our
expectations, neither EML4-ALK v1 nor v3b increased the readings from Cell titer
gro or WST-1 assay compared to the KM control. It is possible that both assays
were not the appropriate measurements of altered metabolic pathways, and/or
experimental conditions were not suitable to observe potential metabolic differences
between the KM and EML4-ALK expressing 3T3 cells. It is not certain if the
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WST-1 measurement
incrased phosphorylation levels are related to high ATP production and/or
metabolism. The highly phosphorylated enzymes potentially regulate amino acid
production, nucleic acid synthesis, and lipid biosynthesis which are regarded as
highly active in cancerous cells.
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111.5 Discussions
EML4-ALK is a fusion tyrosine kinase that is constitutively active and
transforming in 3T3 cells. In order to understand its potential transforming and
carcinogenic mechanisms, we employed the quantitative phosphoproteomic
analyses by mass spectrometry to reveal EML4-ALK induced tyrosine
phosphorylation signaling networks. From the phosphoproteomic analyses, 84
phosphorylation sites are identified. A number of phosphorylation sites are found
to be responsive to EML4-ALK expression.
An important positive control is the ALK pY1 096 levels, which are indicative
of ALK tyrosine kinase activities. EML4-ALK L586M kinase dead mutant (the KM)
expressing 3T3 cells had a minimal level of ALK pY1096, which shows that this
mutation inactivates ALK. In wild type ALK transfected 3T3 cells, ALK pY1096 is
as high as in the EML4-ALK v1 transfected 3T3 cells, indicating that ALK kinase
activities in each condition might be similar. This suggests that the signaling
networks initiated from different cellular locations might be significantly different.
Wild type ALK and fusion EML4-ALK localize at different locations and have
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distinctive activation mechanisms. Wild type ALK is a membrane bound receptor
tyrosine kinase which is activated by unknown mechanisms. The ligands for ALK
are still unknown, and activation mechanisms are predicted to be ligand-mediated
homodimerization followed by autophosphorylation. EML4-ALK is a constitutively
active homodimeric cytosolic tyrosine kinase localized to microtubules. Protein
populations around each kinase's environments are different, and the differences in
signaling networks were revealed between similar ALK kinase activities based on
different localizations. One question that remains to be solved is the potential
activation mechanisms of wild type ALK. The ligands for ALK have not been
discovered yet, and the mechanisms by which ALK tyrosine kinase domain
phosphorylates and fully activate its kinase activities remains unclear. Based on
the growth of wild type ALK transfected 3T3 cells that grow preferentially in contact
with neighboring cells, it is possible that ALK activities are induced by cell-cell
contacts. It remains unclear what proteins expressed on the surface of plasma
membrane have affinities toward extracellular domains of ALK. EML4-ALK v1 and
EM14-ALK v3b are constitutively active kinases and v3b is predicted to have
stronger tyrosine kinase activities (Mano, H, Personal communication).
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EML4-ALK v3b has the highest ALK pY1 096 among all conditions which indicates
that 3T3 cells expressing EMI4-ALK v3b has the highest ALK kinase activities,
whether it is due to the empirical expression level biases or innate differences
between EML4-ALK v1 and v3b.
One important question from all signaling analyses of kinase transfected
cell lines is if the kinase expression level is physiologically relevant because
expression levels can significantly alter substrate specificities (Jones et al., 2006).
In our study design, we focused on detection of tyrosine phosphorylation sites from
3T3 mouse fibroblast cells that were transformed by EML4-ALK expression. This
is the classic model of transformation assay that was used to demonstrate the
transforming activities of BCR-ABL (Daley et al., 1987). 3T3 cell focus formation
assay with EML4-ALK is further complimented by 1L3 dependent BaF3
transformation assays, which is the gold standard for in vivo screening process for
BCR-ABL kinase inhibitors (Daley and Baltimore, 1988). Similar to BCR-ABL,
EML4-ALK is shown to transform 1L3 dependent BaF3 cell lines and growth could
be inhibited by increasing doses of ALK kinase inhibitors. Based on these
characteristics, we hypothesized that analyses of EML4-ALK tyrosine kinase
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in 3T3 cells are relevant for understanding
mechanisms.
One of the important findings from this study is that endogenous EML1 and
EML4 are phosphorylated in EML4-ALK dependent manners, while both the KM
and wild type ALK does not affect EML1 and EML4 phosphorylation levels. These
results were confirmed in 3T3 cells and 293 cells by co-transfection of EML4-ALK
and human EML1 or EML4 followed by anti-EML1 and EML4 immunoprecipitation
and anti-phosphotyrosine blots with 4G10 (Mano, H, Personal communications).
Therefore, EML1 and EML4 phosphorylation by EML4-ALK are not 3T3 cells
specific events, and the phosphorylation occurs at least in two different cell lines.
EML1 and EML4 physically interact with EML4-ALK, which is indicative of a
kinase-substrate relationship. The interaction continued when the EML4-ALK
dependent tyrosine phosphorylation sites on EML1 and EML4 were mutated to
phenylalanine, indicating that these tyrosine phosphorylation sites are not required
for the interaction. Analyses of YF mutants of EML1 and EML4 in the presence of
EML4-ALK with EML1 and EML4 immunoprecipitation followed by
anti-phosphotyrosine blots suggested the presence of additional EML4-ALK
201
signaling network its molecular
dependent tyrosine phosphorylation sites (Mano H, personal communications). It
is possible that there are unidentified EML4-ALK dependent tyrosine
phosphorylation sites on EML1 and EML4 that compliments a loss of a single
phosphorylation site resulting from the YF mutation. Furthermore, EML1 and
EML4 interact with each other in 3T3 cells. While experiments with proper loading
controls are required to make a conclusion, presence of EML4-ALK seems to
increase the interaction between EML1 and EML4, while YF mutation of EML1 and
EML4 decreases such interaction.
Wild type ALK and EML4-ALK transfected cells have increased
phosphorylation levels on many important cellular enzymes in metabolic pathways
(Figure 12).
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Figure 12. Enzymes in metabolic pathways are highly phosphorylated in ALK and
EML4-ALK expressing 3T3 cells. Hyperphosphorylated enzymes are highlighted in
red.
Notably, PKM2 pY390 is highly phosphoryatled in an EML4-ALK dependent manner.
While functional insights of many phosphorylation sites on metabolic enzymes are
still missing, the involvement of metabolic enzymes in cancer homeostasis is
starting to become clear. ENO and LDH-A were highly phosphorylated in an
EML4-ALK dependent manner. While functional outcomes of each
phosphorylation event remain unclear, it indicates that a kinase with high activity
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can potentially reprogram metabolic pathways in order to maintain the high energy
production and biosynthetic demands. Highly proliferative cells such as cancerous
cells requires production of basic cellular materials, such as amino acids, nucleic
acids, and lipids. The highly phosphorylated enzymes potentially regulate amino
acid production, nucleic acid synthesis, and lipid biosynthesis in order for cancerous
cells to continuously divide at high rates.
An important finding from the validation process of phosphoproteomic data
is that EML1 and EML4 seem to interact with many tyrosine phosphorylated
proteins in the presence of EML4-ALK as visualized in Figure 13.
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Figure 13. Schematic diagram of EML4 and EML1 mediated protein
phosphorylation by EML4-ALK. EML1 and EML4 are phosphorylated by EML4-ALK.
Phosphorylated EML1 and EML4 function as adaptors or scaffolds, recruiting
proteins. Proteins bound on EML1 and EML4 are phosphorylated by EML4-ALK
While it remains unclear if EML4-ALK interacts with EML1 directly or if endogenous
EML4 acts as a bridges between EML1 and EML4-ALK, it seem that EML4-ALK at
least partially exists as a part of multi-protein complexes including EML1 and EML4
at microtubules. It is probable that many SH2- and PTB-containing proteins are
recruited by EML1 and EML4 tyrosine phosphorylation sites in EML4-ALK
dependent manners. These recruited proteins may be phosphoryated by
EML4-ALK due to its proximity to the kinase. It is speculative at this point, and
further experiments are required to confirm that EML4-ALK phosphorylates many
proteins that are part of a large protein complex.
In conclusion, the studies conducted in this collaborative project shines
lights on the mechanisms of EML4-ALK signal transductions. EML4-ALK is a
promising therapeutic target for NSCLC patients who are diagnosed as an
EML4-ALK+ subclass. A treatment against the fusion tyrosine kinase BCR-ABL
has been shown to be successful from the history of the BCR-ABL discovery and
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Gleevec development in Chronic Mylogenous Leukemia patients. Fusion genes
are previously thought to play pathogenic roles in hematologic malignanancies, but
not in solid tumors. EML4-ALK is the first example of a transforming fusion
tyrosine kinase in a solid tumor. In order to develop therapeutic compounds
effectively, a better understanding of EML4-ALK signaling mechanisms is vital at
early stages of therapeutic developments. Through a series of experiments in this
collaborative project, we have revealed the tip of an iceberg of EML4-ALK signaling
mechanisms. The summary of proposed mechanisms of EML4-ALK signaling
mechanisms is shown in Figure 14. We hope that further discoveries will follow for
the benefit of NCSLC patients.
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Figure 14. Tip of an iceberg of EML4-ALK oncogenic signaling mechanisms.
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IV. Conclusions
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IV. CONCLUSION
Through a series of connected experiments in this thesis, I have identified a
molecular mechanism by which breast cancer cells adapt to pressures from
anti-estrogen compounds. Tamoxifen resistance mechanisms are complex, likely
multifactoral phenomena. Discovering key differences between Tamoxifen
sensitive and Tamoxifen resistant tumors is critical for better clinical practice. I
have addressed this problem by applying novel phosphoproteomic technology to
understand differences in tyrosine phosphorylation events. The thesis work
described in the previous chapters can be divided into three major sections, which
reflect the specific aims of the thesis.
In the first section, I have derived Tamoxifen resistant cell lines using
previously described methods. Long term low dose Tamoxifen exposure to the
Tamoxifen sensitive MCF7 cell line indeed lead to the development of an acquired
Tamoxifen resistant cell line (MCF7-TAM). In addition, stable overexpression of
HER2 tyrsosine kinase in MCF7 cells (MCF7-HER2) lead to increased growth rates
as well as maintenance of growth in the presence of Tamoxifen.
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MCF7-TAM is a population of Tamoxifen resistant cells that adapted to
pressures from exposure to Tamoxifen. MCF7-TAM's growth profile is essentially
similar to parental MCF7 in the absence of Tamoxifen, whereas complete resistance
against Tamoxifen treatment is observed in the presence of Tamoxifen treatment.
Interestingly, MCF7-TAM maintains a similar ER expression level as parental MCF7.
Despite the similar ER expression level, growth of MCF7-TAM becomes less
dependent on hydrophobic factors present in serum, including estrogen.
MCF7-HER2 cells are populations of MCF7 cells that are expressing
approximately 40-fold more HER2 protein. According to previous work by CC.
Benz et al, HER2 overexpressing MCF7 acquired Tamoxifen resistance in vitro and
in vivo. The in vitro observation was reproduced independently in this study.
MCF7-HER2 cells remain estrogen dependent for their growth based on the growth
profile conducted in estrogen-depleted media.
Both MCF7-TAM and MCF7-HER2 in this study have distinctive growth
profiles. MCF7-TAM is minimally affected by Tamoxifen treatment, whereas
MCF7-HER2 is greatly affected by Tamoxifen treatment compared to MCF7-TAM,
yet sustains a higher level of growth compared to parental MCF7. They represent
215
different models of Tamoxifen resistant populations.
adaption/resistance mechanisms are potentially promising therapeutic targets for
large numbers of breast cancer patients because interventions against such targets
might be beneficial to two different populations of Tamoxifen resistant patients.
In the second section, I profiled the differences in the tyrosine
phosphorylation events of Tamoxifen sensitive and two Tamoxifen resistant cell
lines. One hundred twenty tyrosine phosphorylation sites were identified and
quantified from multiple biological replicates of the phosphoproteomic analyses.
Quantification patterns on each phosphorylation site were compared with growth
profiles of each cell line in order to find relationships between tyrosine
phosphorylation patterns and phenotypic outcomes. We started analyzing
quantification patterns of tyrosine phosphorylation sites on proteins with known
proliferative/anti-apoptotic functions and key downstream components of HER2
signaling networks. For example, P13K regulatory subunit 2 pY605 (P13K R2
pY605) decreased approximately 50% in parental MCF7 in response to Tamoxifen
treatment. Interestingly, P13K R2 pY605 increased approximately by 100% and
70% in MCF7-TAM and MCF7-HER2 respectively in response to Tamoxifen
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Therefore the common
Further analyses suggested correlations
patterns of P13K R2 pY605 and growth profiles of each cell lines. While it remains
to be validated, P13K R2 pY605 is likely to interact with a SH2 subunit of its binding
partner P13K regulatory subunit 1. Such an interaction recruits a P13K p110
catalytic subunit to activate the trimeric type I P13K. From the breast tumor
analysis, we were unable to detect P13K pY605, therefore it remains to be seen if
the same activation occurs in primary tumors.
To measure activities of P13K pathways in Tamoxifen sensitive and
Tamoxifen resistant cell lines, we assessed the level of downstream Akt activity by
measuring pS473 Akt with ELISA. Intriguingly, Tamoxifen resistant cells had
higher pS473 Akt compared to Tamoxifen sensitive cells in response to Tamoxifen
treatment. In addition to ELISA, western blot analyses showed that pS473 Akt is
increased in Tamoxifen resistant cells in response to Tamoxifen treatment (K. Pant,
personal communication). MCF7-TAM cells had significantly higher pS473 Akt
than we predicted from P13K R2 pY605 quantifications. This is potentially due to
inactivation of PTEN due to S-nitrosation in MCF7-TAM cells, leading
deregulated PIP 2 and PIP 3 levels as discussed in the NOS inhibitor section.
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between quantificationtreatment.
Besides the P13K-Akt pathway, we saw correlations between ERK1/2
phosphorylation patterns and growth profiles of each cell line.
phosphorylation levels were similar between parental MCF7 and MCF7-TAM in the
absence of Tamoxifen, whereas ERK1/2 phosphorylaiton levels were 50% higher in
the MCF7-HER2 than two other cell lines. Growth profiles were in good
agreement with ERK1/2 phosphorylation patterns in that parental MCF7 and
MCF7-TAM grew at similar rates, while MCF7-HER2 grew more rapidly than either
cell line. In response to Tamoxifen treatment, parental MCF7 and MCF7-HER2
showed decreased growth rates which corresponds to 50% decreased ERK1/2
phosphorylation sites in each cell line. MCF7-TAM cells maintained comparable
growth rates both in the absence or presence of Tamoxifen, and such growth rates
match to unchanged phosphorylation levels on ERK1/2 in MCF7-TAM in response
to Tamoxifen. In addition to ERK1/2 phosphorylation levels from cell line models,
analyses from primary tumors showed that tyrosine phosphorylation events on four
MAPKs including ERK1/2 were greatly altered in the recurrent tumor that I analyzed.
The results obtained from primary tumors were similar to results obtained from cell
line studies in that ERK1/2 phosphorylation sites were high in Tamoxifen treated
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ERK1/2
samples.
In addition to P13K and MAPK pathways, we identified the
Tamoxifen-induced activations of Src/FAK tyrosine kinases and their downstream
pathways. Such activations were unique to Tamoxifen resistant cells and were not
detected in Tamoxifen sensitive cells. Src and FAK phosphorylation levels were
increased by 50% and 70% in the MCF7-HER2 cells. Numbers of known and
predicted Src/FAK kinase substrates were found to be hyperphosphorylated in
Tamoxifen resistant cells in response to Tamoxifen treatment. In addition to Src
and FAK pathway activation, bioinformatic analysis of the hyperphosphorylated
peptide sequences from Tamoxifen resistant cells predicted the enrichment of AbI
target domains, indicating that AbI kinase may also be activated in Tamoxifen
resistant cells. From the results of primary breast tumor analyses, Src family
kinase and FAK were consistently hyperphosphorylated in the Tamoxifen-treated
recurrent tumor sample. Because few tyrosine phosphorylation sites on known
and predicted Src/FAK/AbI kinase substrates were detected in breast tumor
analyses, it remains unclear if the activities of Src/FAK/Abl kinases lead to the
hyperphosphorylation of their substrates. Analyses of additional human primary
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tumors may strengthen such hypotheses.
In the third section, I conducted small-molecule inhibition experiments to
revert Tamoxifen resistance by inhibiting identified therapeutic candidates from
phosphoproteomic analyses. In order to identify therapeutic targets, we generated
hypotheses from phosphoproteomic data. Candidate targets were
hyperphosphorylated kinases that may play important roles in Tamoxifen resistant
cell lines, including P13K, ERK1/2, and Src/Abl.
In order to inhibit P13K pathways, we used two direct P13K inhibitors
(LY294002 and P1103). Both MCF7-HER2 and MCF7-TAM responded to the P13K
inhibitors in combination with Tamoxifen. Compared to the positive control used in
the inhibition study (Iressa, which was previously shown to revert Tamoxifen
resistance), the extent of growth inhibition by P13K inhibitors were similar to an
extent of growth inhibition of the positive control on MCF7-HER2, while P13K
inhibition did not achieve the desired degree of inhibition in MCF7-TAM.
A second strategy was to inhibit MEK by PD98059 to decrease downstream
ERK1/2 activities. MEK inhibition was effective in MCF7-TAM cell lines, indicating
that MCF7-TAM needs ERK1/2 activity to maintain growth in the presence of
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Tamoxifen. MEK inhibition was less effective in MCF7-HER2 cells than in
MCF7-TAM cells, indicating that MCF7-TAM cells rely on ERK1/2 pathway for their
survival, while MCF7-HER2 relies more on the P13K pathway for growth and
survival in the presence of Tamoxifen. Interestingly, Iressa failed to inhibit the
growth of MCF7-TAM cells, indicating ERK1/2 activation in MCF7-TAM cells is
independent of EGFR activity. As MCF7-TAM increase iNOS expression in
response to Tamoxifen treatment and NOS inhibitor treatment inhibits NO
production, S-nitrosated phosphatases, and decrease viable cell numbers, it is
possible that deactivated phosphatases for ERK1/2 are the potential cause of the
ERK 1/2 activation in MCF7-TAM cells.
I analyzed phosphoproteomic data further in order to identify signatures
from tyrosine phosphorylations that may explain Tamoxifen resistance mechanisms
in MCF7-HER2 and MCF7-TAM cells. Based on comparisons of phosphorylation
sites, protein functions, and bioinformatic analyses of the phosphoproteomic data,
we identified activation signatures of Src/AbI pathways exclusively in Tamoxifen
resistant cells. To probe the functions of Src/Abl pathway activations in Tamoxifen
resistance, we employed the dual-specificity Src/Abl kinase inhibitor Dasatinib
221
(Sprycel), which is an FDA-approved second line therapeutic compound for chronic
mylogenous leukemia. The effects of combinatorial treatment with Dasatinib and
Tamoxifen were compared with positive controls (HSP90 inhibitors, Geldanamycin
and 17AAG). Combinatorial treatments with Dasatinib and Tamoxifen were
effective in suppressing the growth of both MCF7-HER2 and MCF7-TAM to a similar
degree to the positive controls. Inhibition of Ab specifically by Gleevec would be
an interesting experiment because such an experiment would distinguish if the
activated kinase is either Src, Abl, or both. We are planning to conduct this
experiment in the near future.
These results suggest that different Tamoxifen resistant cell line models
utilize multiple pathways that cells rely on for their growth. Identification of
common pathways and key nodes were successful for targeted therapeutic
treatments in Tamoxifen resistant cellular models. In the case of MCF7-HER2,
P13K and Src/Abl pathways may play key roles for growth sustenance. For
MCF7-TAM, ERK1/2 and Src/AbI pathways were up-regulated, and MEK and
Src/Abl were the optimal therapeutic candidates for this model. In order to find
optimal targets for both models of Tamoxifen resistance, Src/Abl pathways were
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tested and found as effective candidates, as use of Dasatinib was shown to be the
most useful option among all compounds we tested in this thesis work. Based on
these in vitro results, I believe that Dasatinib in combination with Tamoxifen would
be potentially more effective than Tamoxifen alone in the clinic. Although further in
vivo analyses in animal models are required, such a combinatorial treatment may
improve the prognosis of hormone receptor positive breast cancer patients.
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V. FUTURE PERSPECTIVES
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V. FUTURE PERSPECTIVES
I have discussed the current state of endocrine therapy to combat breast
cancer, and identified potential therapeutic targets to revert Tamoxifen resistance by
application of phosphoproteomic analyses of tyrosine phosphorylation signaling
networks. While I believe such findings will eventually benefit breast cancer
patients, there are additional important problems which are beyond the scope of this
thesis project. I would like to discuss some of these problems in this section.
Breast cancer and heterogeneity
Breast tumors are heterogeneous populations which consist of many
cancerous cells with different expression levels of various driver oncogenes. In
modern clinical practice, patients diagnosed with breast cancer are histologicaly
categorized into well defined categories of breast cancers based on the expression
levels of diagnostic marker genes such as ER/PR hormone receptors and HER2.
Variation in HER2 and ER/PR expression levels within a single breast tumor cell
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population is one example of heterogeneity.
tumor tissue do not express both diagnostic marker genes even if a patient is
classified as HER2*/ER* by immunohistochemistry. Within such tumors,
HER2~/ER* cells are potentially an optimal target of Tamoxifen treatment, while
HER2*/ER tumor cells are growth-inhibited by Tamoxifen, while ER~HER2* tumor
cells may not be affected. If the majority of the tumor cell population consists of
the optimal targets of a therapeutic regimen, patients are expected to benefit the
most. However, when a patient's immunohistochemical diagnostic results are on a
between HER2*/ER*, HER2^/ER*, ER*/HER2- status, Tamoxifen
treatment may not be effective due to the heterogeneous responses that each cell
type likely to have. Such conditions are, to a certain extent, analogous to
experimental conditions where parental MCF7 and MCF7-HER2 are mixed together
and exposed to Tamoxifen. While it remains difficult to analyze any co-cultured
cell lines, such an experiment may simulate the effects of Tamoxifen treatment to
heterogeneous cell populations with different expression levels of molecular
Due to complex molecular interactions within the cell-cell
microenvironment, it is incredibly challenging to conduct such experiments in cell
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borderline
markers.
All cancerous cells within the breast
culture systems and analyze the effect for such heterogeneous conditions in
two-dimentional, two cell-population cell culture conditions. However, it is
important to note that such co-cultured system may be useful for understanding
complex adaptation mechanisms that heterogeneous cell populations employ.
What I measured in this study are primarily in vitro cell culture models
except for the human primary tumors. It is important to point out that each cell
within heterogeneous populations of the breast cancer cells responds to Tamoxifen
to different degrees and within such heterogeneous populations, complex response
mechanisms help each cancer cell survive and adapt to the treatments. Our
results from the generation of the Tamoxifen resistant derivatives show that different
Tamoxifen resistant cell lines have different growth profiles and responses to
therapeutic compounds. I predict that these models and their growth profiles are
significantly simplified relative to what actually happens in patients' breast tumors
undergoing Tamoxifen treatment. It is possible to speculate that ER*/HER2 tumor
cells may adapt to become Tamoxifen resistant similar to the way parental MCF7
cells become MCF7-TAM cells after long term Tamoxifen
HER2*/ER tumor cells may continue to grow in a similar manner as MCF7-HER2
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treatment, and
situations, we could assume that
heterogeneous cells that consist of ER*/HER2~ tumor cells and HER2*/ER* tumor
cells might utilize the common pathways that our in vitro cell line analyses have
indicated, and therapeutic interventions, such as Dasatinib, may maximize the
benefits from the endocrine treatment regimen. Our finding that dasatinib is
effective against both models of the Tamoxifen resistance needs to be further tested
before it reaches patients, particularly in higher models such as animal studies.
The successful application of combinatorial treatment in patients requires that our
finding must first be reproduced in mouse xenografts models and transgenic mouse
models, which are more biologically relevant conditions.
Differences in molecular consequences of SERM and Al treatment
Modern endocrine therapy for breast cancer gives breast cancer patients
chemotherapeutic treatment options other than SERMs such as Tamoxifen. The
major alternatives are the Aromatase Inhibitors (Als). While both SERMs and Als
target the estrogen receptor to inhibit tumor growth, the modes of inhibition are
229
cells with Tamoxifen treatment. In such
fundamentally different, and it is very important to consider potential outcomes of
each treatment regimen at a molecular scale. Tamoxifen directly inhibits binding of
estrogen on ER to antagonize ER function, particularly at breast tumors. In
contrast, it functions as an agonist in bones to maintain healthy bones which, for
example, decrease risks of osteoporosis. This is beneficial
postmenopausal women who need endocrine replacement therapy. The negative
of the Tamoxifen and other SERMs are that they must modulate
intracellular ER signaling pathways. While the consequences of changes in gene
expressions are predicted, we do not fully understand the long-term outcomes of
such modulations. One of the possible outcomes is an adaptation mechanism that
cancer cells would use to rewire their signaling network in order to survive the
pressure from the SERMs. Tamoxifen and other SERMs are not cytotoxic agents,
rather they are cytostatic agents. While Tamoxifen and other SERMS such as
raloxifen are favorable options for postmenapausal women who choose to benefit
from the treatment for both breast cancer management and bone health
improvement, it is important to consider benefits vs the detriment that rewiring of the
signaling networks may cause in breast tumors with therapeutic resistance.
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aspects
especially for
Als may not be as appealing as SERMs to both premanosausal and
postmenopausal women due to the lack of benefits for bone health, higher costs for
treatment, and lack of large scale clinical trials and history compared to use of
SERMs. The key difference between SERMs and Als is that Als do not directly
interfere with ER in target tissues to inhibit the function of estrogen. Als inhibit
production of estrogen by inhibiting aromatase, a rate-limiting enzyme in estrogen
biosynthesis, therefore limiting availability of estrogen for cancer cells. As there is
no physical modulation of ER by Als, ER signaling networks may be stopped rather
than modulated in a case of SERM treatments. Which treatment would be better
for long term effects at the molecular scale remains unclear at this point. Although
Als slow the growth of estrogen-dependent tumor cells resulting in clinical benefits,
cancer cells are likely to adapt to estrogen-deprived conditions in order to survive
such a condition. Al resistant breast tumors are emerging in breast cancer
patients who were early adaptors of Al treatments. It is important to investigate
resistance mechanisms to other endocrine treatments including Als and other
breast cancer treatments such as anti-HER2 treatment to benefit the entire
spectrum of breast cancer patients.
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In conclusion, phosphoproteomic analysis by mass spectrometry is a
favorable platform to study therapeutic resistance problems because of its unique
capability to collect data in an unbiased manner and facilitate discovery. Such
analyses have important roles in revealing previously unknown signaling events
from which biological hypotheses can be generated. Hypotheses can be tested in
various assays to determine the roles of signaling events in controlling cellular
phenotypes. In the future, phosphoproteomics will be more significant in the
research and development of therapeutic compounds. The contributions that
phosphoproteomics makes will be seen in many disease areas including
therapeutic resistance to cancer treatments.
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